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ABSTRACT 
Background: Levodopa is the most commonly used medication to improve motor 
sequelae in persons with PD (PwPD). However, levodopa and dietary protein compete for 
absorption in the gut and blood brain barrier. Dietary proteins are essential for growth 
and physical functioning, which generally deteriorate with PD progression. Informal 
caregivers (ICG) often assist PwPD with meal and medication management, but have 
reported information deficits regarding dietary and medication management for PwPD. 
Objective: To obtain qualitative information related to dietary knowledge and attitudes, 
and quantitative data on dietary behaviors from PwPD and their ICG.  
Methods: Cross-sectional, mixed-methods study. A semi-structured interview was used 
to collect qualitative data. Quantitative data was collected through use of, two 24-hour 
dietary recalls and the Dietary Screening Tool.  
Results: Ten dyads completed this study. All PwPD were found to be at possible 
nutrition risk, and consume an average protein intake above recommended values. The 
dyads reported misinformation, and limited knowledge surrounding medication and meal 
management. Emerging qualitative themes included Reliance on Caregiver for Buying 
and Preparing meals, Reduced Enjoyment of Foods and Meal Times, Barriers to Dietary 
Intake, Lack of Nutrition Knowledge, Barriers to Medication Management, Management 
of Symptoms, and, Access to Medication Information  
Conclusion: There is a lack of nutrition and medication knowledge, and a need for more 
awareness of the protein-levodopa interaction and strategies to attenuate the fluctuations 
that may occur within the dyads. Interdisciplinary teams for PwPD could help to improve 
health and delay progression of PD if followed early in diagnosis.
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PREFACE 
 This thesis was written to comply with the University of Rhode Island graduate 
school Manuscript Thesis Format. This thesis contains one manuscript: Knowledge, 
Attitudes and Behaviors to Dietary Management in Parkinson’s disease. This manuscript 
has been written in a form suitable for publication in Disability and Health Journal. 
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ABSTRACT 
Background: Levodopa is the most commonly used medication to improve motor 
sequelae in persons with PD (PwPD). However, levodopa and dietary protein compete for 
absorption in the gut and blood brain barrier. Dietary proteins are essential for growth 
and physical functioning, which generally deteriorate with PD progression. Informal 
caregivers (ICG) often assist PwPD with meal and medication management, but have 
reported information deficits regarding dietary and medication management for PwPD. 
Objective: To obtain qualitative information related to dietary knowledge and attitudes, 
and quantitative data on dietary behaviors from PwPD and their ICG.  
Methods: Cross-sectional, mixed-methods study. A semi-structured interview was used 
to collect qualitative data. Quantitative data was collected through use of, two 24-hour 
dietary recalls and the Dietary Screening Tool.  
Results: Ten dyads completed this study. All PwPD were found to be at possible 
nutrition risk, and consume an average protein intake above recommended values. The 
dyads reported misinformation, and limited knowledge surrounding medication and meal 
management. Emerging qualitative themes included Reliance on Caregiver for Buying 
and Preparing meals, Reduced Enjoyment of Foods and Meal Times, Barriers to Dietary 
Intake, Range of Nutrition Knowledge, Barriers to Medication Management, 
Management of Symptoms, and, Access to Medication Information  
Conclusion: There is a lack of nutrition and medication knowledge, and a need for more 
awareness of the protein-levodopa interaction and strategies to attenuate the fluctuations 
that may occur within the dyads. Interdisciplinary teams for PwPD could help to improve 
health and delay progression of PD if followed early in diagnosis. 
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INTRODUCTION 
 Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder 
that currently affects over 900,000 Americans, and is expected to double by 20301-3. 
While the etiology of PD is not well understood, it involves death of dopamine producing 
neurons in the substantia nigra, resulting in loss of sensorimotor control, balance, gait, 
mood, cognition, communication and swallowing1, 4-6. These PD sequelae (consequences 
of pre-existing conditions) lead to time-intensive and expensive management strategies 
including visits to health professionals, medications, surgeries, and complementary health 
approaches ranging from $10-14 thousand dollars per person annually7. In addition to 
public health costs, there are also costs on the informal caregivers (ICG) who spend 39+ 
hours a week on management for people with Parkinson’s disease (PwPD)8. 
 Levodopa is the most common dopaminergic medication used to improve motor 
function, quality of life, and reduce morbidity and mortality in PwPD9. However, 
consumption of dietary protein and levodopa compete for absorption at the gut and blood 
brain barrier9, 10. Dietary proteins are essential as they promote muscle mass retention, 
growth, and physical functioning2. Previous research shows that PwPD consume more 
protein then recommended (0.8g/kg), and a higher protein intake is associated with a 
higher daily levodopa dose over time10. This relationship may be partially attributed to 
protein-levodopa interaction (PLI), leading to higher doses of levodopa which can be 
ineffective in reducing motor sequelae10, 11. Therefore, it is recommended that levodopa 
be consumed between 30-120 minutes before or after a protein food5, 12, 13.  In addition to 
medication timing, a low-protein diet (LPD) or protein redistributed diet (PRD) diet have 
been recommended to minimize the PLI and reduce motor fluctuations in PwPD14, 15. A 
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LPD restricts total daily protein intake to 0.5g/kg/day14, while a PRD limits protein intake 
to 7-15g before the dinner meal with a goal protein intake of 0.8g/kg/day10, 14, 16-18.  
However, there are inconsistent recommendations for PwPD and their ICG on how to 
adequately manage this food-drug interaction14, 16, 19.  
 Informal caregivers (unpaid family member or friend) 20-22 often assist PwPD with 
many care issues including meal and medication management, which become more 
complex as the disease progresses22, 23. Medication management is a “high-level”, 
medically related task, in the caregiver literature22, and ICG have reported information 
deficits regarding dietary and medication management for PwPD, all contributing to the 
feelings of stress surrounding caretaking19, 22-29. Therefore, the purpose of this study was 
to obtain qualitative information related to dietary knowledge and attitudes, and 
quantitative data on dietary behaviors from PwPD and their ICG. It was hypothesized that 
PwPD and their ICG will report limited knowledge, and/or misinformation but a positive 
attitude towards education in regards to dietary management. Also, PwPD will be at 
increased nutritional risk and not adhere the nutrient intake recommendations. This data 
will provide insight to what PwPD and their ICG believe about diet and levodopa 
management for healthcare professionals. 
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METHODS 
 
Participant Recruitment 
 
 The current cross-sectional, mixed-methods study was conducted from October 
2017 to January 2018. People with PD and their ICG were recruited as dyads from PD 
health clinics and rehabilitation centers throughout Rhode Island. All participants were 
community-dwelling adults aged 18 and older, who had access to a telephone. The PwPD 
self-reported their disease stage based on the Hohn-Yahr (HY) scale (stages 1-4)30 and 
reported adherence to taking at least one levodopa-containing medication. Participants 
with PD were excluded if they received calories from enteral/parenteral nutrition, or 
scored ≤18 on the Telephone Montreal Cognitive Assessment (T-MoCA). This study was 
approved by the University of Rhode Island Institutional Review Board.   
Data Collection 
 
 Data were collected during 3 assessments, which included two-telephone calls 
and one home visit. The first assessment was a screening phone call to review inclusion 
criteria, administer the T-MoCA, and complete the informed consent process. 
Assessment #2 was a second telephone call where the dietary screening tool (DST), and 
the first 24-hour dietary recall (24HR) were completed. For the DST, a total score from 
0-105 was calculated and categorized with one of three nutritional risk levels; (<60) at 
risk, (60-75) possible risk, and (>75) not at risk31. The Nutrition Data System for 
Research was used to collect 24HR data by use of the multiple-pass interview approach 
and, distribution of the foods amount booklet for adequate recall32. Assessment #3 was a 
home visit to the dyad, where anthropometric assessments (height, weight and calculated 
BMI), a past medical history questionnaire, the second 24HR, and a 21-question semi-
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structured interview were completed.  
Moderator Guide 
 Semi-structured interview questions were created by the research team to explore 
3 domains, 1) Eating Environment, 2) Dietary Intake and, 3) Medication Management 
(Table 1). Questions were piloted with 3 PD dyads with similar inclusion criteria to 
determine content validity and understandability of the interview. All interviews were 
audio-recorded, transcribed verbatim and coded using thematic qualitative content 
analysis33.  Structural coding, using questions and key phrases from the moderator guide 
was used to categorize the data into codes, then the codes were systematically reviewed. 
The primary author and an undergraduate researcher reviewed and coded the transcripts 
separately, then discussed their findings to identify the most common themes, and 
generated the final themes together. Qualitative content was summarized and direct 
quotes were used to illustrate the perspectives of the participants (Table 2). Participants 
with PD and their ICG are identified in the text as “PD”, or “ICG”, followed by a number 
that was assigned sequentially as surveys were completed.  
Data Analysis 
 
 Descriptive statistics and data from the questionnaires and 24HR were analyzed 
using SPSS Version 25 (IBM Corp, New York). Normality was assessed using skewness 
and kurtosis. Categorical variables are reported as numbers and percentages, and 
continuous variables are reported as mean ± standard deviation. All data collected from 
the moderator guide was analyzed using NVivo 11 QSR (International Pty Ltd, Victoria 
Australia).    
 
  
 
8 
RESULTS 
Demographics  
 Ten PwPD and their ICG participated in this study. Table 3 displays all 
demographic data. Mean ages of the participants were, 68.7±8.5 years (range 50-82 
years) for the PwPD, and 69.4±5.6 years (range 57-78 years) for ICG. Seventy percent of 
the PwPD and, 30% of were ICG were males. All of the PwPD and 90% of the ICG were 
retired. All of the PwPD and 60% of the ICG had at least an associates degree. PwPD had 
been diagnosed with PD for 11.4±4.9 years (range of 8-19 years) and had been taking 
levodopa for 6.9±3.84 years (range 2-15 years). Mean scores on the T-MoCA was 
20.30±1.56. The qualitative results are presented according to the moderator guide 
domains. Additional themes are incorporated within each of those domains.  
Dietary Intakes  
 This domain covered knowledge of recommended dietary intakes and attitudes 
about food and nutrition since the diagnosis of PD. Two emerging themes came from this 
domain (Table 2a). In the Barriers to Dietary Intake theme, all of the participants 
explained some barriers related to PD sequelae that has affected dietary intake. The ICG 
explained digestive issues that pose as a barrier to the types of foods that they buy and 
prepare. Another barrier was the modifications of foods. Many participants reported no 
difficulty with chewing and swallowing but, when asked what kind of dietary changes 
they have made since being diagnosed with PD, the answers related to changes due to 
swallowing difficulties that have affected the foods they consume. Other participants 
described how the motor sequelae as a result of PD act as a barrier because they impact 
the way they get the foods into their mouths. Despite the barriers, a majority of the PwPD 
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reported consuming a healthy diet, however they reported an inclusion of sweets due to 
the decreased taste of foods, and sweet foods containing a stronger flavor. 
 The other emerging theme was, Range of Nutrition Knowledge for PD, where 
many PwPD and their ICG reported some knowledge, but confusion about the PLI. Some 
were not aware that dietary proteins compete with levodopa or, recently learned about 
this interaction. The participants were also unaware of the PRD and LPD that may help 
decrease some of the motor fluctuations they experience. Due to the range of knowledge 
surrounding the protein altered diets, many participants spoke about the challenges that 
they would have following these diets. Despite this range of nutrition-related knowledge 
the majority of the participants reported that they would be very interested in learning 
“anything you have” about the medication-meal management.  
Eating Environment  
 
 This domain included two items, which addressed PwPD and their ICG attitudes 
around food and some of the behaviors they exhibit during the mealtime process (Table 
2b). In the Reliance on ICG for Buying and Preparing Meals theme, participants reported 
that ICG play a large role in buying and preparing foods in the home. For approximately 
half of the dyads, the PwPD helped plan what foods to buy but the ICG do most of the 
purchasing and preparation, especially for foods requiring more advanced preparation. 
Also, in the Reduced Enjoyment of Foods and Meal Times theme, both PwPD and ICG 
described a decreased enjoyment in the eating experience and an avoidance of going out 
to eat because of PD progression.  
Medication Management  
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 This domain gave insight into self-reported behaviors around medication intake, 
three themes emerged (Table 2c). The first theme, Barriers to Medication Management, 
showed that in most of the participants, the responsibility of managing medication was on 
the PwPD. However, many PwPD described challenges remembering to take the 
medication at the right time due to busy schedules. Many used of devices and strategies 
to help overcome their challenges to taking their medication but even those could result 
in their own problems. Another theme that arose was, Management of Symptoms, despite 
some barriers to taking the medication, when asked about how the medication manages 
daily PD symptoms all of the participants discussed a positive effect if the medication 
was working that day. Finally, the theme, Access to Medication Information, described 
how the participants accessed medication information. A majority mentioned that they 
would find information online or talk with their peers. Most described that they would 
not feel comfortable contacting their doctor or a health care professional because they are 
not readily accessible, and some of the information provided is not easily understood. 
Although many participants had means of accessing medication information, most 
recognized the importance of staying up-to-date with information and expressed positive 
attitudes toward learning. 
Dietary Data 
 In addition to the qualitative data about diet and medication management within 
this population, dietary assessments were used to better understand results in relation to 
the qualitative and quantitative data. Mean score on the DST was 66.4±13.9, which 
categorizes this population at possible nutrition risk and further investigation found that 
30% of PwPD were not at nutrition risk, 40% were at possible risk, and 30% were at 
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nutrition risk. Mean BMI for the PwPD was 27.1±4.7 (overweight) with 30% classified 
as normal weight, 50% as overweight and 20% obese. All dietary data is displayed in 
Table 4. Participants consumed an average of 1955.7±678.2 calories, at 4.5±1.4 eating 
times per day. Eighty percent of the PwPD consumed their medication and meals within 
30 minutes of each other. Timing of meals and levodopa intakes are in Figure 1. Average 
protein intake per kg of body weight was 0.9±0.2, the recommendation is 0.8g/kg/day, 
and in this sample 30% were below and 70% were above this recommendation. 
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DISCUSSION 
 
 The goal of this study was to explore the knowledge, attitudes, and behaviors of 
dietary management in PwPD and their ICG through dyadic interviewing and dietary 
assessments. The major findings of this study were the range of knowledge related to 
food-medication management and, not adhering to protein recommendations for this 
population. PwPD and their ICG have received little information related to the PLI and 
were confused about meal and medication timing, which is consistent with a qualitative 
dyadic study by Shin et al19, that revealed participants feeling stress and uncertainty 
related to medication and diet management19. In addition to the qualitative data found, 
dietary intake information confirmed the lack of adherence to protein-levodopa timing. 
Participants took their medications less than the 30-120 minutes recommended prior to 
consuming a meal (80%), and more protein than the RDA (0.9g/kg), with more grams of 
protein during the day than at night. These findings are also consistent with a previous 
PD dietary studies which found that, 75% of PwPD consumed protein with their levodopa 
and more protein during the daytime10, 34.  
 Levodopa is the most effective medication to control PD motor sequelae9, 
therefore it is important to identify possible interactions and barriers to compliance so 
PwPD can receive the greatest symptomatic benefits. All of the participants reported 
difficulties talking to their healthcare providers about medication and most resorted to the 
internet or peers, which may not provide valid information. Registered dietitians (RDs) 
are trained in managing food-drug interactions and can help provide reliable information 
to PwPD and ICG.  However, RD’s are often excluded from the management of PD. 
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Therefore, future research should further investigate the use of RDs in the management of 
PD, and ways to increase access to PD health information.  
 The PwPD in this sample were responsible for managing their own medication, 
which is inconsistent with previous research which indicated that ICG are highly 
involved in medication management22. This could be attributed to the study participants 
being highly educated and screened for cognitive impairments. Regardless, the PwPD 
reported that levodopa has positive effects on their motor sequelae when it is “working”. 
Due to the reported range of knowledge about the PLI and the medication fluctuations, 
PwPD may benefit from a LPD or PRD as both have been effective in reducing motor 
fluctuations and total levodopa dosag17, 18. 
  The ICG took on the majority of the food purchasing and preparation in this 
sample, which is consistent with previous literature, where ICG have been found to 
become the primary food provider when food and food-related work become a problem35. 
The PwPD experienced decreased enjoyment around food and the eating environment 
which can be contributed to PD sequelae like, decreased taste, gastrointestinal (GI) 
distress, taste and motor flucutations. Person’s with PD described a loss of taste that 
affected their enjoyment of foods; previous research has shown a decreased desire for 
most foods, except for those with strong tastes, such as ice cream36. In addition to taste, 
GI distress decreased eating enjoyment due to decreased gastric emptying rate which will 
increase abdominal distention, discomfort, nausea and early satiety and bloating in 
PwPD5.  
 Other sequelae that decreased food enjoyments included, chewing and swallowing 
and motor functioning. Previous research has found that the prevalence of dysphagia in 
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PwPD varies (35-80%) due to the majority of PwPD self-reporting no swallowing 
difficulties, but showing evidence on a bedside swallowing test37. While this study did 
not directly assess swallow function, symptoms associated with dysphagia were 
identified and affected the foods participants consumed. Additionally, the reported 
difficulties in using utensils while eating show the need for an occupational therapist 
(OT) however, only 13-25% of PwPD have utilized OT services because most patients 
are not referred to their services until the later stages of the disease, when it may already 
be too late38. Therefore, the inclusion of a multidisciplinary team of RDs, SLPs and OTs 
early in PD diagnosis could allow PwPD to maintain more activities of daily living as the 
disease progresses and deter some of these barriers to dietary intake. 
 The second aim was to identify the nutritional risk status and dietary intakes of 
PwPD through two dietary assessments. Optimal nutritional status is difficult for PwPD 
to maintain due to cognitive decline, gastrointestinal issues, difficulty swallowing, and 
PLI1, 5, 6. In the current sample, PwPD were found to be at possible nutrition risk, which is 
consistent with previous research39. Table 5 compares DST and NDSR data to show 
quality and variety of the participants diets. While there are no formal dietary guidelines 
for PwPD our findings show participants are not meeting the general recommendations 
for the Dietary Guidelines for Americans (DGAs), or those that are specific for PwPD5,40. 
While this population was meeting the recommendations for macronutrient and calorie 
intakes, on average they did not meet the 30-35g recommendation of fiber per day to 
alleviate constipation5, or the vitamin D, calcium, magnesium and potassium 
recommendations for muscle and bone health40. Meeting the recommendations for all 
nutrients is important to improvement in nutritional status and slow disease progression5. 
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The large standard deviations of the results, exhibit the heterogeneity of PwPD which 
makes standardized intakes difficult to quantify, therefore all dietary recommendations 
should be individualized to fit the needs of PwPD40. The DGAs may be utilized early in 
the diagnosis but once levodopa therapy is introduced, protein intake may need to be 
altered so the medication absorption can be improved5. Additionally, when educating 
PwPD, health professionals should be aware of cognitive deficits when presenting 
information to PwPD and should present information multiple times and provided written 
materials.  
 In the current study, PwPD and their ICG showed a range of knowledge, and 
misinformation about dietary recommendations for PwPD but showed a positive attitude 
towards receiving education in regards to managing dietary protein intake and levodopa.  
Also, this population’s dietary behaviors showed them to be at possible nutrition risk and 
consuming more than the RDA for protein, which may call for future dietary research to 
explore diet quality and variety in PwPD.  However, due to the small, homogenous 
sample size this information cannot be generalized to a larger population of PD. 
Additionally, this sample included mostly white and highly educated participants which 
is common in the PD literature, future research should focus on targeting other races and 
education levels.  Also, due to the cross-sectional, descriptive design of the study, only 
one-time point was obtained and more longitudinal approaches should be considered for 
this population. All of the dietary data is based on self-reports which may affect the 
accuracy, but in order to increase some validity, food amount booklets were sent to all 
participants and referred to, and the multiple pass methods was utilized during the 24HR. 
However, despite these limitations, this study is unique because it included both PwPD 
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and their ICG to gather mixed methods data which will be beneficial for interdisciplinary 
teams working with this population. This research could be modified to attenuate to 
additional neurological disorders which affect 1 in 7 households3. 
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CONCLUSION 
 Current findings confirm lack of nutrition and medication knowledge and the 
need for nutrition education around food-drug interaction and managing disease 
sequelae’s impact on dietary intake. Overall, the results of the study identify areas for 
education that have the potential to attenuate motor fluctuations secondary to medication 
intake and maximize management of disease symptoms overtime. Future research should 
focus on interdisciplinary teams for PwPD could help to improve health and delay 
progression of PD if followed early in diagnosis.  
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TABLES AND FIGURES  
 
Table 1: Qualitative Domains  
Eating 
Environment: 
1. Describe the most challenging aspects of preparing and eating 
meals since the diagnosis of PD 
2. Who is responsible for buying and preparing food in your home? 
Dietary Intake: 1. How has your diet changed since being diagnosed with PD? 
Prompt: are there any foods that you have stopped or increased 
eating due to your diagnosis? 
2. How would you describe your current diet?  
3. Who have you spoken with about your diet and what have they told 
you? 
4. Is there anything you would like to know about the foods that you 
eat or your daily nutrition in general? Prompt: what questions or 
concerns do you have about your daily eating or about the foods you 
eat in general?  
5. What is your understanding of a PRD or LPD? Prompt: the PRD 
limits protein during the day and includes more protein at dinner, 
the LPD limits all protein during the day and at dinner   
6. What challenges would you anticipate if you were following a PRD 
or LPD? 
7. What difficulties do you have chewing or swallowing your food or 
beverages? Prompt: what fluids do you have difficulties consuming? 
How often do you cough during meals? How much more time does it 
take you to eat than before the diagnosis? 
8. Do you modify the textures or consistencies of your foods or 
beverages? Prompt: Do you consume ground meat instead of whole 
pieces? Do you soften or puree your vegetables? Do you use 
products like “Simply Thick” to thicken the fluids you consume? 
Medication 
Management: 
1. Describe your greatest challenges to taking your levodopa 
medication as prescribed by your doctor? 
2. How you do cope or overcome the challenges to taking your 
levodopa medication as prescribed by your doctor? 
3. What is your daily levodopa schedule? 
4. What information have your doctor and/or pharmacist provided 
bout the timing of your medication? 
5. How do you time your food and medication intakes? 
6. How do you obtain information about your levodopa medication? 
7. How well does levodopa manage your daily symptoms? Prompt: do 
you ever feel shaky, unsteady or sluggish after consuming your 
medication? 
8. What do you know about the food-drug interaction between 
levodopa and protein? 
9. What information would you like to know about your medication 
management? Prompt: how interested are you in learning more? 
10. Do you rely on your caregiver to receive your levodopa medication? 
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Table 2: Qualitative Themes  
a. Dietary Intake 
-Barriers to Dietary 
Intake 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“It’s a Mediterranean diet with cookies and stuff like that.” –
PD8 
“We eat a lot of fish and chicken, occasionally red meat and 
my worse thing is cookies, and chips occasionally.” –PD9 
“My taste has gotten worse over the years, I think I eat foods 
by the memory of what they taste like.” –PD3 
“I have noticed some foods don’t have as much taste, (my 
doctor) said it’s understandable that I like to eat chocolate 
because it has a strong flavor.” –PD2 
“There are some digestive concerns every once in a while. 
Sometimes spaghetti and meatballs can make his stomach a 
little acidic so I have to be careful about what we eat and how 
it will affect him.” –ICG1 
“(He stopped eating) anything tomato because he has that 
burning tongue syndrome.” -CG3 
“I like to eat salads but I am concerned because once I did 
have choking.” –PD1 
“I’m more conscious in how I eat food, I cut smaller pieces, 
especially meat or something, lettuce or salad I cut into small 
pieces.” -PD1 
“Certain kinds of lettuce seem to be harder, mostly what I use 
is the heart of romaine, tomatoes, cucumbers, things you can 
feel going down. I think I was putting spinach in a salad, 
trying to use that, and the spinach became a choking hazard. I 
had already also put spinach in meatloaf and he said I can’t 
swallow parts that have spinach, so I don’t anymore.” –ICG1 
“I’ve had trouble consuming fluids… water or juice, but very 
rarely, it’s not a problem.” –PD1 
“Sometimes I choke on water of coffee, so I take smaller 
sips.” –PD5 
“I don’t have a lot of difficulty except a couple of times I was 
eating autumn soup and I aspirated a little on the soup and 
choked really bad.” –PD6 
“I initially had trouble with things like crackers and pretzels 
so I stopped eating those really dry things. I’ve reintroduced a 
lot of that overtime just being more mindful and having liquid 
nearby.” –(PD8) 
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-Range of Nutrition 
Knowledge for PD 
 “I don’t modify the textures, if there is something like steak 
or a pork chop I cut it up into much smaller pieces than he 
used to have.” –ICG4 
“Sometimes when you drink water, something that’s very 
crumbly, he will have difficulty, start coughing, so he has to 
drink water after it. And every once in a while, when he 
swallows water or diet coke or something he’ll cough, but not 
very often.” –ICG4 
“Sometimes water tends to go down the wrong hole. I cough 
on occasion, now and then.” –PD3 
“I stay away from beef because it’s too difficult to slice it 
sometimes…” –PD3 
“Using utensils, like gripping them and getting food into my 
mouth without it falling in my lap. I take smaller bites and it 
takes me longer to eat” –PD5 
“I went through a period of difficulty getting it (food) into my 
mouth but that was before the dosage of carbidopa/levodopa 
that I’m taking now.” –PD6 
“I have seen (diet information) online, I read things from the 
APDA, I saw that mentioned once that it may be some help in 
the absorption of the dopamine but I don’t recall it being 
something that they necessarily were recommending it just 
was sort of mentioned” –ICG1 
“I am interested in trying to time the medication and the 
protein consumption to see it we could make it happen that 
the sinemet goes in a half-hour before the meal is consumed 
and see is that makes a difference or does it have to be an 
hour before or two hours after. I would be very interested in 
knowing those things –ICG1 
“I didn’t know and I don’t know how bad it is and I still don’t 
know how long I should wait when I eat” –PD6 
“The doctors don’t give you information about anything” –
PD8 
“I get concerned when I take my Sinemet pill, is that 
supposed to compete for absorption with fats and so it’s best 
if you don’t take it with a heavy mean anyway but it also 
makes you nauseous that’s why I start with crackers in the 
morning.” –PD2  
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 “I know that too much protein slows down the carbidopa but 
other than that no. I never really experienced that though, I 
know about it.” –PD5 
“I was never told anything, until recently about protein being 
a hindrance to absorbing dopamine, so I’ve been a little 
concerned about when I am eating meals and when I am 
taking medications, should I be waiting a half hour or should 
I be waiting an hour? This is one issue I’ve been worrying 
about.” –PD6 
“Well the question that I have and have always had, and 
people always give me answers but they’re not really answers 
is the interaction between protein and Sinemet, 
carbidopa/levodopa is confusing and really challenging 
because 99% of the food that I eat has protein in it and some 
sources say that even a trace amount of protein can interfere 
with the carbidopa/levodopa. That is the only medication that 
is having an effect on my brain and helps me be in more 
control.” –PD8 
“My understanding is that any amount of protein in the body 
at the same time that carbidopa/levodopa is in the body 
prevents is from entering the brain, it’s just a block- no 
sinemet allowed here.” –PD8 
“Because he actually requires more protein now, he has the 
protein supplement, because of the energy level, because of 
the PD, muscle support for sure, so a low protein diet would 
be something that I am not keen on.” –ICG1 
“I think he would get tired and be rather listless and the other 
part would be trying to figure out having low protein during 
the day and then why at night? He’s not going to do anything 
then, that’s when we settle down. I’d rather say high protein 
in the morning and decrease it during the day but even that 
makes the meals off balanced.” –ICG1 
“Yeah, I think it would be challenging. You’d have to start 
and think about when you took your pills, when you ate, how 
much protein you could have, so yes it would be 
challenging.” –ICG4 
“That I’m getting enough protein –PD5 
“I don’t want my wife to have to make two meals. I’ll eat 
whatever she eats so that would be a challenge.” –PD6  
“It would be really challenging for me because I like to eat 
small amounts of food a lot.” -PD8 
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b. Eating 
Environment  
-Reliance on ICG 
Buying & Preparing 
Foods 
 
 
-Reduced Enjoyment 
of Foods & Meal 
Times 
 
“She’s taken over. Yeah, I used to do it all, I used to do a 
quite a bit of cooking too.” –PD3 
“He doesn’t prepare the meals, he can throw together a 
sandwich if he needs to but I’m the cook.” –ICG1 
“I used to like to experience and enjoy many foods of 
different kinds (of food), now most foods don’t have much of 
a taste and I also have to force myself to eat to put weight 
on.” –PD1  
“He doesn’t have his taste buds as good as they were so he 
doesn’t enjoy a lot of stuff. I would say the things he enjoys 
the most is probably sweets.” –ICG3 
“We don’t go out to restaurants anymore because it’s too 
much of a hassle.” –ICG5 
“I am just not interested (in eating) anymore.” –PD11 
c. Medication 
Management 
-Barriers to 
Medication     
Management  
    
 
 
 
 
 
 
 
 
 
    
 
 
 
 
“Frequently what we have is a therapy sometime like today 
when we came home it was about 12:15 and he was hungry, I 
was starving so we had lunch right away, but he was due for a 
pill at 12 so he had the pill, he ate lunch within that half hour 
before it would have been fully absorbed.” –ICG1 
“When you’re retired your day ought to be empty but ours 
winds up having a lot of going to the YMCA for exercise 
classes and Doctors visits and I wind up in a position where I 
pretty much have to take the pill very close to a meal or put it 
off longer than is appropriate.” -PD 2 
“My greatest challenge, taking it on time –PD11. Taking it on 
time and taking it throughout the day, you stop when you 
know you’re not doing anything so –CG11. Yeah like if I’m 
home, I tend not to take it –PD11. I try to remind her because 
I see the signs when she runs out –CG11. Yeah like it bothers 
him more than it bothers me, I don’t mind being off my meds, 
I just move slower, but he says my face looks different and I 
just move differently –PD11.  
“I use an alarm in my phone to remind me when to take the 
1:00pm and 6:00pm pills. It’s not uncommon for me to be in 
a seminar when it would have gone off, and I’ve got my 
phone turned off and I forget to take it until later.” -PD2 
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-Management of 
Symptoms  
   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
-Access to Medication     
Information 
“I had a cell phone all set up but he won’t carry a cell phone 
so that has been a real problem, I am trying to come up with 
an apparatus that he will use and carry.” -CG 4 
“I have pill box that I have in the drawer that has my vitamins 
in it too, but then for lunch I would forget to take it if it 
wasn’t out.” -PD 7 
“We try writing down each time I take a dosage. So, if I take 
carbidopa-levodopa every 4 hours, 4 times a day, if I start at 
say 8am, I write 8am and know my next dose is due at 12 
then 4. If I don’t write it down it’s like, did I take it at 7 
yesterday because I was up earlier or did I sleep in and take it 
at 9? - PD10. 
“The impact of levodopa is pronounced it’s just a question of 
how long it takes” –PD1 
“I guess it controls some tremors, my jaw used to shake a lot 
more visibly than it does now but it’s pretty successful” –PD2  
“I think it helps a lot, I’d say maybe 50-60%.” –PD3 
“There are days that I think I’m just as well off without pills, 
but if I do that I realize that the pills really are doing some 
good” –PD4 
“If he takes them every four hours on time they make a huge 
difference.” –ICG4 
“If she misses a dose she will feel it if it goes past the four 
hours.” –ICG5 
“When it’s working it works pretty well. I can walk without 
any assistance, I walk with a can though because I have a 
problem with my left hip. When I’m not doing well I will use 
a walker and even that is a struggle” –PD6 
“I couldn’t manage my life without it. I notice sometimes 
feeling a little more sluggish or stuck, frozen is the term they 
like to use so it’s really challenging to be at my best without 
taking the medication.” –PD8 
“If you have high protein, it just feels like you’re not 
medicated –PD11 
When (she’s) on the medication most people can’t even tell 
she has Parkinson’s.” –CG11 
“I would ask my doctor but he’s kind of hard to get a hold of 
so we look it up.” –PD2 
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“Absolutely none from the doctor, just how many times he 
could take it but that’s all, not when” –ICG1 
“Look online and the handouts you get at the pharmacy.” –
PD5 
“I look online but the sheet comes with my medication, I get 
2-3 pages of information and I scan it, I mean I read it when I 
first got it but now I scan it in case there is something 
different.” –PD7 
 “Online but probably more so on the information from the 
pharmacy. You know how CVS sends 3-4 pages of stuff you 
can’t understand, that I can’t understand. Usually that or 
medical journals they have good information. And here at the 
gym they post things that are pertinent, groups and surveys” –
PD10 
“Well I’ve spoken about it with my peers in the support 
groups and LOUD Crowd.” –PD8 
“Online and talking to other people with Parkinson’s.” –PD11 
“We’ll sit in the cafeteria when the guys are in LOUD, they’ll 
talk about the down time, who has down time, who doesn’t. I 
find a lot of information when I sit with the ladies -ICG3  
“You just have to educate yourself and have a great support 
group which we have at URI, we are so lucky. That is a 
blessing that is worth so much and I think it’s a constant 
battle but it’s also you have to keep educating yourself on all 
the new stuff and it never lets up- ICG4 
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Table 3: Participants Demographics 
 PwPD ICG 
Age  68.7±8.5 69.4±5.6 
Gender %(n) 
Men 
Women 
 
70(7) 
30(3) 
 
30(3) 
70(7) 
Working Status %(n) 
Working 
Retired  
 
0(0) 
100(10) 
 
10(1) 
90(9) 
Highest level of education %(n) 
Some college 
Associates degree 
Bachelor’s degree  
Master’s degree 
Doctoral degree 
 
0(0) 
10(1) 
30(3) 
30(3) 
30(3) 
 
40(4) 
10(1) 
40(4) 
10(1) 
0(0) 
Other health issues  
Diabetes  
Hypothyroidism 
Hypertension 
Heart condition  
 
10(1) 
10(1) 
10(1) 
20(2) 
 
BMI %(n) 
Normal 
Overweight 
Obese 
27.1±4.7 
30(3) 
50(5) 
20(2) 
Height (in) 67.2±3.0 
Weight (kg) 78.9±16.5 
Years since diagnosis  11.4±4.9 
Years on levodopa 6.9±3.8 
Levodopa dose/day (n) 3.9±1.0 
T-MoCA 20.3±1.6 
DST %(n) 
Not at risk 
At possible risk 
At risk 
66.4±13.9 
30(3) 
40(4) 
30(3) 
Eating times/day (n) 4.5±1.4 
Meals/day 2.9±0.3 
Snacks/day 1.8±1.4 
Protein intake (g/kg) 0.9±0.2 
Protein pre-dinner (g) 39.8±19.0 
Protein post-dinner (g) 32.5±7.8 
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Table 4: Nutrient Breakdowns  
 
PwPD Intakes Range DGA Male DGA Female 
Calories 1955.6±678.2 905.5-3214 2,000 1,600 
Total water (ml) 1884.9±791.2 819.7-3372 3700 2700 
Carbohydrate (g) 232.2±79.8 98.7-308.6 130 130 
Fiber (g)  
Soluble                            
Insoluble                      
23.2±9.4    
6.3±2.9    
17.3±7.7                   
6.5-29.7 28 22.4 
Fat (g) 
Monounsaturated 
Polyunsaturated 
84.2±43.5 (38%) 
32.3±20.2 
17.8±9.6 
24-179 20-35% 
 
20-35% 
 
Protein (g) 
Animal 
Vegetable 
72.3±20 
44.2±12.3 
17.8±9.6 
43.6-106.3 56 46 
Vitamin D (mcg) 
Thiamine (mg) 
Riboflavin (mg) 
Niacin (mg) 
Vitamin B6 (mg) 
Vitamin B12 (mcg) 
Folate (mcg) 
Calcium (mg) 
Iron (mg) 
Magnesium (mg) 
Potassium (mg) 
Sodium (mg) 
377±296 
1.6±0.5 
1.9±0.6 
21.3±6.8 
1.8±0.7 
4.2±2.5 
415.1±186.9 
839.6±410.3 
14.8±8.2 
324.5±179.5 
2599.8±977.5 
2544.5±715.2 
28.9-1042 
0.6-2 
0.7-2.7 
11.4-29.5 
0.6-3.1 
1.5-10.1 
154.5-712.5 
266-1066.5 
5.7-33.1 
132.5-762 
1715-3540.5 
1253.5-3493 
600 
1.2 
1.3 
16 
1.7 
2.4 
400 
1,000 
8 
420 
4,700 
2,300 
600 
1.1 
1.1 
14 
1.5 
2.4 
400 
1,200 
8 
320 
4,700 
2,300 
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Table 5. Comparison of Dietary Groups between 2 Dietary Assessments 
 DST (points) NDSR (servings) 
Fruits 11.2 (15) 2.2 (2 cups) 
Vegetables  11 (15) 3.7 (3 cups) 
Whole Grains 10.4 (15) 1.7 (3.5oz.) 
Lean Proteins 7.5 (10) 5.9 (6oz.) 
Added Fats, Sugars & Sweets 11.9 (25) 5.8a 
Dairy 4.5 (10) 1.3 (3 cups) 
Processed Meats  7.5 (10) 0.7a 
Supplements  50% 50%b 
a= There are no specific DGA recommendations for number of servings  
b= Percentage of participants using supplements  
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Appendix A: Review of Literature 
 
I. Introduction  
 Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects 
over 900,000 Americans and by 2030 the prevalence is expected to double1-3. 
Parkinson’s disease causes motor and non-motor sequelae (consequences of pre-
existing conditions), such as resting tremors, slowness of movement, cognitive decline, 
depression, sensory changes, difficulty swallowing, and gastrointestinal issues, all of 
which can negatively impact dietary intake and nutritional status1, 5-7.  The motor 
sequelae are commonly managed with levodopa therapy to improve motor function, 
quality of life, and reduce morbidity and mortality in persons with PD (PwPD) 10. 
Informal caregivers, those who provide the majority of care without monetary 
compensation, assist PwPD in managing the disease sequelae and levodopa 
medication23, 24. Additionally, caregivers are involved with all aspects of dietary 
management such as menu planning and food purchasing and preparation, since PD 
sequelae reduces the PwPD’s ability to complete these tasks24, 30. Dietary protein is 
essential as it promotes muscle mass retention, growth, and physical functioning, which 
generally deteriorate with PD progression1, 2, 11. However, dietary protein competes 
with levodopa for absorption, therefore timing of levodopa and protein intake needs to 
be managed properly11, 20. Dietary management is critical for PwPD as they are at 
increased risk of poor nutritional status39, and need to minimize the protein-levodopa 
interaction (PLI)17. Although dietary modifications exist for PLI management, PwPD 
and their caregivers report misinformation regarding which dietary modifications are 
optimal20. The purpose of this review is to investigate the sequelae associated with PD, 
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and the treatments currently available to help PwPD and how their caregivers 
contribute to a large amount of management of sequelae.   
II. Parkinson’s Disease  
 Parkinson’s disease is most prevalent in the fastest growing US population, adults 
aged 65 and older3, and affects 1-2% of the population, globally4. The etiology of PD is 
not well understood, but involves neuronal call death from the brain stem to the 
cerebral cortex that result in loss of sensorimotor control, balance, gait, autonomic 
function, mood, cognition, communication and swallowing1, 4-7. The disease often 
presents with presents with the loss of dopamine-secreting neurons within the 
sunstantia nigra and the presence of Lewy bodies41. Therefore, there is a decrease in the 
amount of dopamine, a neurotransmitter that regulates movement and emotional 
response. When there is not enough dopamine present, non-motor and motor sequelae 
will occur. Early signs of the disease include tremor, postural instability and 
bradykinesias, which prompt a visit to the neurologist but, often go untreated as these 
sequela are often attributed to the normal aging process4. The most common type of PD 
is idiopathic, which presents in 90% of PwPD4, and often includes a young onset and, 
akinetic and tremor predominance but each PwPD will present with their own set of 
sequela. Due to the heterogeneity of PD, and the widespread pathology of PD the onset, 
progression and etiology of most sequelae are not understood1.  
 Parkinson’s disease is often staged according to motor sequelae1, 31, by the five 
stages of the Hoehn and Yahr (H&Y) scale with stage 5 being most advanced31. These 
scores are assigned by the neurologist and can fluctuate as the disease progresses and 
medications are altered.  Scores are evaluated as the disease stage from 1, “unilateral 
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disease”, 1.5 “unilateral plus axial involvement”, 2 “bilateral disease without 
impairment of balance”, 2.5 “mild bilateral disease with recovery on pull test”, or, 3 
“mild to moderate bilateral disease, some postural instability, physically independent”, 
4 “severe disability, but still able to walk or stand unassisted”, and 5 “wheelchair-bound 
or bedridden unless assisted”31. These stages will fluctuate with disease progression and 
overall management of the disease, but give PwPD a guide as to where they stand in the 
progression of their disease.  
 Management of PD is time-intensive and expensive management strategies 
including doctors’  and other health professional appointments, medications, surgeries, 
and complementary health approaches ranging from $10-14 thousand dollars per person 
annually8. Due to the neurodegenerative nature of PD, a caregiver will be warranted to 
take over all activities of daily living (ADLs) as the disease progresses42. 
Pharmacological management is the most frequently used management in PD, and 
often presents with the most confusion and difficulties in compliance among PwPD and 
their caregivers according to qualitative research23. 
III. Pharmacological Management of PD  
 The neurodegenerative, movement disordered mature of PD causes motor and 
non-motor sequelae result in an increased burden on PwPD and their caregivers, which 
effect physical, social, emotional and nutritional statuses9. In order to uphold overall 
quality of life, and slow progression of disease, there have been pharmacological 
treatments studied and recommended to treat the sequelae41. Recommendations are based 
on the individual due to the heterogeneity of PD41. 
a. Motor Sequelae Management  
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Medications used to treat the motor sequelae associated with PD act on the 
neurological interactions in the striatum41. Recommendations are to initiate medication 
when patients begin to experience functional impairment or social embarrassment from 
their symptoms41. The choice of initial medication depends on the patient’s specific age 
and what symptoms they are experiencing41.  The three most typical medications used for 
PwPD are 1) monoamide oxidase type B inhibitors (MAOBIs), 2) dopamine agonists and 
3) levodopa41. These three produce dopaminergic effects; dopamine agonists and 
levodopa work to bind to and activate dopamine receptors, while MAOBIs inhibit the 
breakdown of dopamine. Additional drugs that may be used include beta-blockers, 
anticholinergic and amantadine drugs41, which act to block postsynaptic receptors for 
other neurotransmitters in the striatum, therefore making dopamine more available. 
 In the early stage of PD, when motor sequela are generally mild, MAOBIs, 
anticholinergic, beta-blockers, or amantadine drugs are typically the first line of 
treatment41. However, there has been inconclusive evidence on the overall effectiveness 
of these drugs41. In a recent meta-analysis of MAOBIs in early PD, there was only a 
small but significant symptomatic benefit shown with rasagilin43, 44. Anticholinergic 
medications like, trihexyphenidyl, benztropine and procyclidine, have been shown to 
improve some motor fluctuations compared to placebos in clinical trials but, have not 
been shown to significantly help tremors44, 45. The beta-blocker, propanol is the most 
effective when controlling tremors in PwPD44, 46-49.  Additionally, The International 
Parkinson and Movement Disorder Society recommends the use of amantadine’s, 
unspecified for motor system management as mono- and adjunct therapy, despite the 
mixed evidence supporting its treatment for PD44, 50. These drugs are known to be 
  
 
38 
effective in the early stages of the disease but as motor sequelae become more 
pronounced, or they are diagnosed earlier, stronger medications are warranted41.  
 Dopamine agonists (carbidopa), and/or levodopa are typically prescribed as PD 
progresses and motor sequelae become more prominent and activities of daily life are 
impaired41. Dopamine agonists may be prescribed before levodopa in a more advanced 
stage of PD, or as a first line of treatment if the patient is under 60 years of age. 
Dopamine agonists result in less negative side effects than levodopa, and are typically 
tried first in young on-set PD. However, dopamine agonists have been shown to cause 
compulsive behaviors in PD, especially compulsive eating, which can result in 
overweight and obesity and has a negative impact on health status41. Therefore, it may 
only be an effective treatment for a short time, before a full-levodopa treatment is 
warranted.  
 Levodopa therapy has shown to provide the greatest symptomatic benefit for PD 
including, less freezing gait, daytime drowsiness, edema, hallucinations and risk of 
impulse control disorders. Levodopa is quickly metabolized in the plasma and has a short 
half-life of 1.5 hours51, 52. Upon administration, levodopa crosses the blood-brain barrier 
in order to be converted into dopamine, replacing the neurotransmitter deficient in PD. 
Most PwPD start levodopa at 50mg one time per day, and then three to four times per day 
equaling 100-200mg53. Levodopa is commonly combined with a dopamine agonist 
(carbidopa) so there is an increase of levodopa in the central nervous system which will 
improve one’s ability to tolerate the drug by reducing adverse side effects like nausea, 
from peripheral decarboxylation51. There are several ways levodopa therapy can be 
administered such as, immediate-, controlled and co-administration. 
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 Immediate-release (IR) medications combine carbidopa and levodopa to inhibit 
metabolism in the periphery and allow an increase in central nervous system (CNS) 
availability10. The IR formulas have short half-lives and therefore need to be taken more 
frequently44, 52, 54, 55. Because of the increased frequency in taking IR formulas, overtime 
there is a shortening of clinical response and higher, more frequent dosing to compensate 
for the change in pharmacodynamics44, 52, 54, 55.  These changes due to chronic levodopa 
use, increases the probability of over and under dosages which lead to motor 
complication. Motor sequelae have occurred as early as 5-6 months after levodopa 
treatment56. After 2 years only 20% of patients experience sustained benefits57, and after 
5 years, 70% experience on-off fluctuations and dyskinesia’s58, 59. As time on IR 
levodopa increases, wearing off becomes more frequent, levodopa doses need to be given 
in increasing frequency.10  
 Controlled-release (CR) medications are degradable polymer matrices that slow 
the release of levodopa into the gut10. These medications produce less “off” time and 
more “on” time10.  Although levodopa levels are more stable, the absorption of CR 
levodopa is delayed, making symptom relief less predictable60. Research has shown that 
in the long-term (5 years), there is no difference in degree of motor fluctuation and 
dyskinesia’s between CR and IR medications in patients with moderate to severe motor 
fluctuations49.   
 Co-administration strategies of IR and CR have also been tried in PwPD in order 
to increase effectiveness of levodopa therapy. This strategy has shown to increase total 
exposure of IR by 30-40% and prolongs levodopa half-life to 2.4 hours10. This 
combination inhibits peripheral levodopa metabolism and allows more levodopa to enter 
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the CNS10. This strategy has been shown to produce levodopa plasma profiles similar to 
CR but with higher levodopa fluctuations61. However, the scheduling of this formula may 
increase the burden or complexity of the medication schedule as the first dosage needs to 
be taken early in the morning and restricts the CR at night10.  
 Levodopa is the most effective medication to control PD motor sequelae in, 
independent of patient age and severity that will be prescribed depending on onset of PD 
and degree of sequelae. However, there is other issues associated with consumption. 
People with Parkinson’s should talk with their healthcare providers on which treatment 
would be most beneficial for them and their lifestyle. It is also important to take 
nutritional status into consideration when discussing levodopa therapies as long-term use 
of this medication can negatively impact nutritional status which has been shown to 
already deteriorate with PD progression. Specifically, one major nutritional concern is the 
contraindication with protein, which will be discussed in greater detail later.  
b. Non-motor Sequelae Management  
 Close to 100% of PwPD present with one or more of the non-motor sequelae. 
Non-motor sequelae can be broad, like depression or cognitive impairment, or narrow, 
like hallucinations, orthostatic hypotension, or sialorrhea (increase in saliva) 41, 62-64. Non-
motor sequelae may present as part of disease, or as a side effect of a PD medication used 
to treat the motor sequelae (described above) and both, the sequelae and the medication 
will fluctuate as the disease progresses41. It is important to consider the pharmacological 
management of these sequaela as they may affect overall nutritional status, dietary intake 
and quality of life in PwPD.  
 A common broad non-motor sequelae is depression that often occurs throughout 
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the disease course and may worsen as the disease progresses41. In 2013 a systematic 
review65, and two meta-analyses66, 67, reviewed antidepressants effect on depression and 
found no statistically significant superior antidepressant compared with a placebo, but 
tricyclic antidepressants were more effective than selective serotonin receptor inhibitors 
(SSRIs) and dopamine agonists (mirapex). The AMA suggests that SSRIs and selective 
serotonin norepinephrine reuptake inhibitors (SNRIs) can be effective in managing 
depression despite the little evidence found in PwPD41. Despite the positive effects, 
tricyclic antidepressants are not frequently recommended due to the adverse effects that 
may occur in older adults who are cognitively impaired41. Dopamine agonists are also an 
option to target depression as it can improve motor symptoms as well41. The use of 
antidepressants in PwPD is very common to treat depression and 13-22% of those who 
are community-dwelling, and 50% of those who are institutionalized use 
antidepressants68, which also an effect on cognition and quality of life (QoL), and can 
lead to a decreased nutritional status. Therefore, it is crucial to identify eating patterns in 
PwPD.  
 There have been few studies that have assessed the treatment of cognitive 
impairment in PwPD.  The most studied class of drugs have been cholinesterase 
inhibitors in five placebo-controlled trials69, 70, that have shown improvements in global 
assessment scale scores, cognitive function, behavioral disturbance and ADLs ins patients 
with Parkinson’s disease dementia. However, with these drugs, the AMA believes that 
meaningful clinical benefit of these drugs is variable and unpredictable in PwPD, and 
research into other drugs to help with this non-motor sequelae needs to be conducted41. 
Cognitive impairment has shown to decrease nutritional status, performance in activities 
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of daily living31, 71, 72, quality of life, and increase caregiver burden26  
The narrow non-motor sequelae, hallucinations, orthostatic hypotension, and 
sialorrhea may also occur as a part of normal disease sequelae or may be a side-effect of 
a PD medication41.  Hallucinations, perceptions of things that are not present, have been 
treated with clozapine, but there is a risk of leukopenia, which will require frequent blood 
monitoring41. Also, for those with dementia, rivastigmine has shown to reduce 
hallucinations73, while donepezil has shown to reduce hallucinations in those without 
dementia74. Domperidone, has been recommended by the AMA to control dopamine 
agonist- and levodopa- induced, hypotension especially when the medications are 
introduced together41. The use of anticholinergic drugs for the treatment of sialorrhea has 
been recommended by the AMA, however, these are not well tolerated in older adults 
with cognitive dysfunction41. Glycopyrrolate may be very effective and better tolerated 
due to limited blood-brain barrier penetration, and botox injections can be effective and 
well tolerated, but with more injections, the risk of adverse effects like dysphagia may 
limit use41. 
 Pharmacological management strategies for motor and non-motor sequelae are 
often the first line of treatment for PwPD41. It is important to consider all medications 
that the PwPD is taking, and be aware of the adverse effects that may impact nutritional 
status, dietary intake and quality of life. Other approaches to compliment 
pharmacological management of non-motor sequela may include dietary or occupational 
health measures like, increasing salt and fluid consumption, elevating the head of the bed, 
and quickly drinking 2, 8-oz glasses of cold water in the case of orthostatic 
hypotension41. For more broad motor or non-motor sequelae, surgeries and ancillary 
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services are recommended to be used in conjunction with pharmacological management 
for better health outcomes75 
IV. Non-Pharmacological Management  
 Parkinson’s disease is a progressive disease that causes decline in motor, 
cognitive and nutritional functioning. Pharmacological management is often started at 
disease onset and will be monitored and altered throughout its progression. In addition to 
pharmaceuticals, there are potential non-pharmacological management strategies like, 
surgeries and ancillary services recommended for symptom management and to slow 
disease progression76. The most common surgery for PwPD is Deep Brain Stimulation 
(DBS), while the most common services for PD include physical and exercise therapies, 
occupational therapy, speech therapy, and a growing need for nutritional therapy77. There 
is currently no cure for Parkinson’s disease so, the recommended medications, surgeries 
and services will all work in combination to manage the disease progression76.   
a. Deep Brain Stimulation  
 Deep brain stimulation (DBS) has recently emerged as an effective treatment for 
PwPD who no longer receive symptomatic relief from medications76. Worldwide, there 
are over 100,000 PwPD who have undergone DBS, and more are expected to receive the 
treatment76, 78. An electrode implanted in the brain sends an electrical current to a neuro-
stimulator in the chest, which blocks dysfunctional signals that cause motor 
fluctuations79. Research conducted on the benefits of DBS have shown profound 
improvements related to motor and speech sequelae79-81. A recent meta-analysis of 6-
randomized controlled trials found that DBS improved motor functioning while off 
medication79. Schupbch et al80 found significant and sustained motor sequelae five years 
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after surgery. Another study compared speech one year before and after in one group who 
was treated with DBS, and another who was only treated with medication81. Only those 
who received DBS experiences a significant decrease in speech intelligibility, strained 
voice and stuttering, only from those who received DBS81. While DBS may impact 
speech, it is an effective treatment option for managing overall disease sequelae76. 
However, because this is not the first line of treatment, and is only utilized in a small 
population of PwPD, the use of ancillary services is recommended with the use of 
pharmacological management, whether DBS was preformed or no to reduce side effects 
and optimize symptoms outcomes76.  
b. Ancillary Services  
 The American Academy of Neurology recommends regular utilization of 
physical, occupational and speech therapies for PwPD82. These therapies have been 
shown to improve quality of life, dysarthria and hypophonia in PwPD38, 83-85. The positive 
effects of rehabilitation services slowing disease progression in PD have been well 
documented. However, a recent study showed that only 25% of US Medicare 
beneficiaries with PD received rehabilitative therapies in a 3-year period86, potentially 
due to poor dissemination and implementation of PD research. Therefore, it is important 
for PwPD to have a multidisciplinary team where primary care doctors and neurologists 
recommend these rehabilitation services for better management of PD progression. 
Regular attendance at these rehabilitation services, or one-on-one sessions has shown 
improvements in motor function, activities of daily living, speech volume, cognition and 
quality of life86.  
Physical and Exercise Therapies  
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 Physical activity in the management of PD was first introduced in 195087. It was 
not until three decades later that experimental studies were used to recognize the benefits 
that physical and exercise therapies had on motor fluctuations in people with Parkinson’s 
disease (PwPD) 88, 89. Physical and exercise therapies are the most utilized rehabilitation 
service for PD and randomized controlled trials show its significant impact on improving 
motor and non-motor sequelae, activities of daily living (ADL), speech volume and 
QoL90. Common physical and exercise therapies include resistance training, tai chi, water 
exercises, robotic gait training, dance, virtual reality, aerobic training, boxing, Nordic and 
downhill walking91, 92. As most of these exercises serve to improve physical mobility and 
functioning, activities such as dancing, water exercises, virtual reality training, and 
Nordic walking have also allowed PwPD to enjoy greater health and wellbeing91, 92.   
 Many studies have demonstrated that older adults enjoy different activities that 
are not typical exercises because they add enjoyment. Tai chi has shown to provide the 
most improvement in postural stability, movement function and gait in people with mild 
to moderate PD93-95. These improvements can be maintained into the long-term (3 
months) and still prove to be beneficial as the disease progresses93-95. Also, dancing is a 
complex motor skill that involves postural stability, weigh shifting, inter-limb 
coordination, single leg-stance activities and trunk rotation96. Older adults have been 
identified as a population to enjoy dancing as a form of physical activity97-99. In PwPD, 
this exercise has shown benefits in body function, disease severity and QoL99. 
 More traditional exercises like resistance and aerobic training, walking, boxing 
and water exercises. Resistance training which may include exercise machines, has 
resulted in improved lower limb muscle strength, balance and motor symptoms100. 
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Aerobic training through use of a cycle ergometer was used as aerobic training, 
improvements in functional mobility, ADL, balance, disease severity and walking101. 
Different types of walking training, Nordic and downhill have both been tested and show 
benefits in functional mobility, gait, QoL and improvements in walking, respectively102, 
103. Boxing is becoming a common activity for PwPD because there have been 
improvements in functional mobility, ADL, gait and balance in PwPD104. Water exercises 
have been thoroughly tested in older adult literature as the effects of buoyancy and 
hydrostatic pressure of water has contributed to a decreased risk of falls105. For PwPD, 
the aquatic environment may enhance balance, reduce freezing or gait and fear of falling 
and increase movement of amplitude and speed96, 106, 107. 
 In addition to traditional physical activities, there have been many technological 
creations to exercise to complement physical activities. Robotic gait training involves a 
large device where one’s legs are strapped into a machine and moved on a treadmill108, 
109. This type of complementary exercise has improvements in functional mobility, 
balance, disease severity, gait108, 109. Virtual reality and exercise gaming have also been 
proposed to complement and practice to exercise therapy in those with neurological 
disorders110, 111. With this technology, there improvements have been shown in functional 
mobility, ADL, gait, QoL, balance and movement disorders110, 111. A final technology, the 
whole-body vibration, transits energy into your body, forcing your muscles to contract 
and relax each second, which can provide modest improvements in the short term for 
mobility, gait, balance and disease severity112. Although these new therapies can improve 
motor functioning, when compared to physical therapies the improvements are not as 
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positive and it is suggested that these technologies are used in conjunction with additional 
physical activities91.  
Occupational Therapy  
 Occupational therapists are trained to help PwPD maintain their usual level of 
self-care, work and leisure activity for as long as possible113. Possible interventions may 
include re-organizing the daily routine, learning new skills for alternative or adaptive 
ways to carry out activities, providing or advising on specialized equipment or resources 
and patient education (like devices to increase mealtime experience) 113. Multiple studies 
have examined the use of an occupational therapist and results have shown that only 13-
25% of PwPD have utilized their services113-115. Most patients are not referred to an 
occupational therapist until the later stages of the disease where the occupational therapist 
helps to reduce daily stress, minimize disability and improve quality of life despite the 
natural increase in impairment113.  
Speech Therapy  
 Over 89% of PwPD will have a speech disorder and/or dysphagia throughout the 
progression of their disease which will require pharmacological and nonpharmacological 
management strategies86. Communication and speech deficits are often apart of the 
disease sequelae, and are difficult to manage with medications or DBS alone4, which will 
require the specialty of a Speech Language Pathologist (SLP) to provide ancillary 
services. The most common treatments for communication deficits include, the Lee 
Silverman Voice Treatment (LSVT), or effort-based therapy, speech and voice therapy 
and musical therapy4. The best outcomes have been shown with LSVT, which focuses on 
increasing vocal loudness, voice quality, speech ineligibility, articulation116-118, and more 
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evidence has been found surrounding positive changes in facial expression119 and 
swallowing120. This treatment is time-intensive as it includes 16, 1-hour long sessions, 
delivered over 4 weeks119, but has been tested in an 8-week time period with the same 
positive results121.  
 Treatments for dysphagia are patient-dependent and will depend upon the 
physiology of the swallowing for the safest approach4. Often, modification of textures 
and consistencies of foods and liquids with thickeners will depend on barium swallow 
testing. Honey-thickened liquids have been shown to result in the fewest aspiration 
events, but for patient QoL purposes, the chin-down feeding approach was better 
accepted122. Exercise programs like, expiratory muscle strength training (EMST) have 
also been used to improve cough, swallow function, penetration/aspiration scores, and 
hyolaryngeal function123, 124. 
 Parkinson’s disease sequelae will progress overtime and warrant the need for 
ancillary services. While it would be beneficial for ancillary services to be started early, 
most will not start until later.  The motor (tremors and rigidity) and non-motor (dysphagia 
and altered gastric emptying) sequelae can be managed with DBS, physical, speech and 
occupation therapies and pharmacological therapies. However, these sequelae may 
contribute to a larger issue of under/over-nutrition which will call for nutritional services 
to be a part of the interdisciplinary team.  
V. Dietary Management  
 
 Optimal nutritional status is difficult for PwPD to maintain as cognitive decline, 
weight fluctuations, difficulty swallowing and gastrointestinal issues contribute to 
inadequate dietary intakes1, 5-7. Poor dietary intake result in poor nutritional status and 
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risk39. Currently, there have not been any nutrition assessment tools that have been 
validated in PwPD.  However, the Dietary Screening Tool (DST) and Mini Nutrition 
Assessment (MNA) are reliable and validated tools to identify severity of nutritional 
status and risk in older adults, and have been used to identify PwPD with impaired 
nutritional status and at nutritional risk32, 39, 125. There have been dietary 
recommendations suggested that address PD sequelae and medication interaction17, 
however no person with PD is alike and all will require a nutritional assessment for 
individualized dietary recommendations. Therefore, the review will address several 
nutritional issues that relate to PD that should be taken into consideration when caring for 
a patient with PD. 
Cognitive Decline 
 Dementia, the most common cognitive symptom, occurs in 40% of PwPD and is 
associated with an accelerated progression of disease and risk for institutionalization29, 126, 
127.  Cognitive decline has shown to affect interest in food through loss of taste and smell 
senses, and eating habits in PwPD128, 129. The memory loss associated with cognitive 
decline affects ones’ ability to remember to eat, placing the feeding on the caregiver, if 
applicable130. Also, over the last few years there has been evidence of the gut-brain axis 
that links the gut to the source of PD pathology that eventually progresses to 
neurodegeneration131. The inclusion of phytochemicals and antioxidants from berries, 
wine, caffeine have been suggested to have neuroprotective effects and may slow 
progression of PD132.  
Weight Changes  
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 Weight status in PD will vary based on disease stage and severity. Studies have 
shown that the  prevalence of obesity among PwPD is 50% higher than the general 
population133. Obesity is associated with impaired glucose control, hypertension, 
dyslipidemia, and cardiovascular disease, all of which will further effect PwPD, aside 
from typical disease sequelae133. If the PwPD is not obese at diagnosis, they may become 
obese preceding initial diagnosis due to an increase in energy intake, or the initiation of 
DBS or a dopamine agonist medication, all of which will increase energy intake134, 135.  
Although weight and energy intake may increase during these times, a major sequela of 
PD is weight loss and eventual undernutrition, 5, 136 partly due to rigidity and dyskinesia 
(~400kcals/day) 137-140. Weight loss is associated with increased energy expenditure, early 
satiety due to decreased gastrointestinal motility, olfactory impairment, bulbar 
dysfunction and decreased baseline dopaminergic stimulation of central reward 
systems135. 
 Additionally motor sequela have an negative effect on activities of daily living 
related to food intake like, shopping, preparing, and cooking which may also reduce food 
intake141. A 3-year longitudinal study showed that increasing energy intake to 
compensate for the increased expenditure was not effective in preventing weight loss, 
suggesting that the idea of progression weight loss in PD may be related to other factors 
like malabsorption125. Weight fluctuation is a major concern in PD due to muscle wasting 
which can impact cognitive functioning and ability to carry out activities of daily living, 
which will increase caregiver burden5.  
Dysphagia  
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 Difficulty swallowing (dysphagia) is a common sequela that presents in up to 
80% of PwPD142-144. Tremors and rigidity occurs in the head and neck regions with PD, 
therefore chewing and swallowing can be effected145, 146. There are functional changes in 
the oropharyngeal and esophageal motility of the neck which impair peristalsis and low 
sphincter activity to further disrupt gastric functioning147, 148. Assessment of dysphagia 
includes clinical parameters like, changes in BMI, HY-scale, food and drink retention, 
and questionnaires addressing self-reported perception of swallowing149. Dysphagia is 
believed to play a role in weight loss in PD, because it results in prolonged feeding 
periods, mealtime interruptions, and avoidance of certain foods, specifically solid foods 
145, 146 150, 151. Liquid foods are usually associated with dehydration and risk for aspiration 
due to dry oral organs (dry mouth) 150, 151. Both textures can all lead to nutrient 
deficiencies.  Texture-modified diets and the use of thickened whole-formulations and 
ready-to-eat foods are often recommended for use as they can be safer to swallow in 
PwPD5. Dietitians and SLPs should work together to identify the best texture for the 
individual and if it is meeting their nutrient needs. If nutrient needs are not able to be met, 
a gastrostomy may be indicated5.  
Gastrointestinal Issues  
 Impaired gastric emptying rate is a severe motor sequelae that increasingly occurs 
with PD progression152. Changes in gastric motility (ex. reduced absorption related to 
dopaminergic activity) play a large role on small intestine transit, through enhanced 
production of bacteria and malabsorption due to alterations of the enterocytes153, 154.  
Impaired gastric emptying in PwPD is that it may prolong the exposure of levodopa to 
the decarboxylase enzyme in the gastric mucosa, delaying absorption in the guts and its 
  
 
52 
overall efficiency in reducing motor fluctuations153, 154. Decreased gastric emptying rate 
will increase abdominal distention, discomfort, nausea and early satiety and bloating, 
which may reduce the enjoyment of eating and energy intake in PwPD5.  Constipation 
is the most commonly reported gastrointestinal sequela for PwPD, and impacts nearly 
60% of PwPD throughout the course of their disease5. Increased transit time and gut 
dysbiosis are factors that contribute to constipation, and are contraindicated in PwPD as 
this will highly degrade their levodopa medication and reduce its availability5. Dietary 
strategies to address constipation include increase in fiber and water intakes. People with 
PD have been shown to consume adequate fiber to alleviate their constipation however, 
this population has also been shown to consume less water, which negatively effects stool 
consistency and bowel habits11. Therefore, when education PwPD on how to alleviate 
constipation, increases in water and fiber must be discussed in unison11. 
a. General Recommendations for Dietary Intake 
 Nutrition assessment is critical for PwPD as the associated motor and non-motor 
sequelae can negatively impact dietary intake and nutritional status and vice versa. 
However, there is a lack of specific dietary recommendations for PwPD to manage 
sequelae. People with PD will need to monitor nutrients like protein, water, fiber, 
calcium, vitamin D and B6 and folate. It has been recommended that PwPD should 
consume at least 1.5L of water  per day and consume a minimum of 30-35g of fiber per 
day5. The dietary guidelines for Americans (DGAs) may be used to form a base for 
recommendations in this population as they promote a balanced and nutritious diet that 
includes fruits, vegetables, protein, grains and dairy40.  The recommendations for this diet 
include 10-35% of calories from protein sources, 45-65% of calories from carbohydrates 
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and 20-35% of calories from fats with <10% of calories from added sugars and saturated 
fats, but all breakdowns and items from food groups should be individualized to fit the 
needs of the person with PD40. The Mediterranean diet has been studied within this 
population and is associated with reduced PD incidence and later age of diagnosis5. It is 
typically 50-60% carbohydrates, 12-15% protein and 25-30% fat, which is a small change 
from the DGAs5. The Mediterranean diet focuses on fruits, vegetables, nuts, seeds, fish 
and other lean protein, including fish high in DHA and EPA like salmon, tuna and 
swordfish that have been shown to improve neuronal health and slow PD progression 132. 
The DGAs or Mediterranean diet may be utilized early in the diagnosis but once 
levodopa therapy is introduced, protein intake may need to be altered so the medication 
absorption can be improved5.  
b. Dietary Protein Patterns  
 Dietary protein is essential as it promotes muscle mass retention, growth, and 
physical functioning1, 2, 11.  However, all dietary protein can interfere with absorption of 
levodopa-containing medication in the gut, blood brain barrier, and the peripheral 
nervous system19, 155. Specifically, the large neutral amino acids, phenylalanine, tyrosine, 
and tryptophan, which are commonly found in protein foods like dairy products, nuts, 
seeds, salmon and turkey, will have the most competition. Therefore, it is recommended 
that levodopa be consumed anywhere from 30-120 minutes before or after a protein-
containing meal or snack11. Persons with PD consume up to 50% more protein than the 
Recommended Dietary Allowance (RDA), 1.2g/kg vs. 0.8g/kg respectively, and a higher 
protein intake is associated with a higher daily levodopa dose over time, due to the 
contraindication of protein and levodopa11.As stated above the higher doses of levodopa 
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can be ineffective in reducing motor sequelae11, 12. Also, studies have shown that 22% 
(n=364)156 and 38% (n=52)155 of their participants alter the timing of their dietary protein 
intake to reduce motor fluctuations.  There have been PD-specific dietary 
recommendations, the LPD and PRD, that aim to reduce PLI experienced by PwPD but 
both may not maintain a healthy diet11, 15, 16, 18, 19.   
 The American Academy of Neurology recommends a LPD or PRD to minimize 
PLI and reduce motor fluctuations in PwPD 15, 16. A LPD restricts total daily protein 
intake to 0.5g/kg/day15.  Low protein diets in conjunction with levodopa have been tested 
in randomized clinical trials in an attempt to reduce motor sequelae in PwPD. Two 
studies have reported on the effectiveness of motor fluctuations with levodopa on five 
protein altered diets ranging from 10g/day (0.15g/kg/day in 70kg person) to 2g/kg/day18, 
19. The most control on motor symptoms occurred in the diets providing 0.5g/kg, also, as 
protein intake increased to 2g/kg, there was a decrease in symptom control. Participants 
in these studies continued to follow the 0.5g/kg protein diet 2-12 months after the study 
ended and were able to reduce their levodopa dosage from 20-42%18, 19. The results from 
these studies suggest that restricting protein is effective in controlling PD sequelae and 
may reduce the dependence on levodopa therapy.  However, although participant 
acceptance was shown, other studies have not and this may not be the best option due to 
outcomes changes like lean body mass, muscle strength and ADL’s which were not 
measured in the present studies, but all may be impacted by low protein intake, especially 
in the aging population1, 2, 11. 
  The PRD may be a better option for aging adults with PD as it focuses on 
reducing dietary protein prior to the evening meal, and consuming an unlimited amount 
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of protein at the evening meal11, 15, 17-19. This diet does not limit total protein and most 
studies have tested between 7-15g of protein before the evening meal with a goal of 
0.8g/kg of protein daily (70kg body weight= 41-48g at dinner) 157-160. In a case-controlled 
study that investigated 600 PwPD, overall daily protein intake influenced levodopa-
related motor complications11. A daily dietary protein intake 10 grams over the 
individual’s recommendation of 0.8/g/kg (70kg body weight= 66g) was predictive for an 
increase in levodopa dose by 0.7mg/kg/day (70kg body weight =~50mg additional 
levodopa/day). A multivariate regression analysis determined an inverse association 
between PRD and motor fluctuations (p=0.046)11. From this study, it can be speculated 
that levodopa dosage may increase at a slower rate, may be effective for a longer time 
and therefore help with motor fluctuations for a longer time, if the PRD with protein 
intake at 0.8g/kg/day is practiced.  
 There are multiple studies that support the use of Mediterranean and modified 
protein diets for PwPD5, 11, 15, 17, 19. Also, the use of low-protein supplements may be used 
to meet dietary recommendations157. Other dietary patterns such as, the consumption of 
dairy products (milk, cheese, ice cream and yogurt), canned fruits and vegetables, diet 
sodas (due to the aspartame), fried foods, beef have shown to negatively affect PD 
progression, but have not been as extensively studied and have shown inconclusive 
results132. The conflicting dietary evidence may add to the confusion that PwPD and their 
caregivers already experience with the disease20, 29. 
VI. Caregivers  
 Parkinson’s disease is the second most prevalent neurodegenerative disease that 
affects the ability to perform ADLs, participate in social activities and access medical 
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care42. Additionally, dementia, the most common cognitive symptom, occurs in 40% of 
PwPD and is associated with an accelerated progression of disease and risk for 
institutionalization29, 126, 127. Therefore, PwPD often require formal (paid) and informal 
(unpaid) caregivers are necessary to provide physical, psychosocial and cognitive support 
for PwPD42. The scope of this review will focus on informal caregivers which spend up 
to 39 hours of care per week and, the costs of caregiving have shown to incur the second 
largest economic burden on a family9.  
 It is estimated that 80% of caregivers for PwPD are informal and, are typically a 
spouse/partner or other immediate family member161. Informal caregiving for those with 
neurological disorders has been extensively studied and has showed improved health 
outcomes, treatment adherence, quality of care and decreased risk of institutionalization 
for the PwPD162-165. However, the time and efforts put into caregiving have negative 
effects on the caregivers’ quality of life, especially if a woman is caring for a male with 
PD42. The burden associated with caregiving for this population is often due to the many 
medications, therapies, doctor’s appointments and overall decline in functional ability that 
are associated with PD which the caregiver must take on25. Through the use of 
qualitative, quantitative, and mixed-methods studies, caregivers often report an 
information deficit regarding dietary and medication management for PwPD, all 
contributing to the feelings of stress regarding care of PwPD20, 23-30.  
 Caregivers are highly involved in medication management in PD23. A qualitative 
study by Shin et al20 investigated the challenges and strategies to medication adherence in 
16 PwPD and 5 caregivers. In this patient-caregiver dyad study, the participants’ main 
concerns were increased cost of medication, medication compliance and decreased 
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levodopa response overtime. Specifically, the dyads reported feeling stress and 
uncertainty about the timing of levodopa and meals20. The reported information deficit 
regarding PLI in this study affirms the need to identify the specific knowledge and 
attitudes regarding dietary protein, levodopa management and overall dietary habits in 
PwPD as is has not been the aim of qualitative research thus far. It is important to include 
caregivers in dyadic studies when assessing PwPD because caregivers often shoulder the 
burden of PD progression as the cognitive status of the PwPD may be compromised due 
to disease sequelae24, 25, 29, 39, 126, 127.  
 
VII. Conclusion  
  
 There is often confusion within the PwPD-caregiver dyad for effective dietary 
protein modification when taking levodopa-containing medications15, 17, 20. Persons with 
PD should limit protein when consumed concurrently with levodopa during the day to 
attenuate motor fluctuations19, 155, 166, 167. However, consistent recommendations are not 
available; various protein levels, and timed delays between medication and meal 
consumption exist11, 20.  Informal caregivers help manage daily tasks for PwPD including 
medication and meal management because PD sequelae typically decreases the ability to 
function independently23, 25. As PwPD have been identified as a population at possible 
nutrition risk, caregivers should be cognizant of foods that promote optimal health and 
attenuate PLI. The purpose of this cross-sectional, mixed methods study is to obtain 
qualitative information related to dietary knowledge, attitudes, and behaviors in regards 
to PLI as reported by PwPD and their caregivers, and to assess nutritional risk and daily 
dietary intake within PwPD. This data provide insight to what PwPD and their caregivers 
believe about diet and levodopa management for healthcare professionals. 
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Appendix B: Extended Methodology 
 
 
Methods: 
 This cross-sectional, mixed-methods study was conducted from October 2017 to 
January 2018 when approval was granted from the University of Rhode Island (URI) 
Institutional Review Board (IRB).  People with Parkinson’s disease and their ICG were 
from, posting of flyers and personal visits to, PD health clinics and rehabilitation centers, 
and hospitals and universities throughout Rhode Island. In order to participate, all 
participants needed to be community-dwelling adults aged 18 and older and have access 
to a telephone. The PwPD needed to self-reported their disease stage based on the HY 
scale (stage 1-4)31 and adherence to taking at least 1 levodopa-containing medication. All 
ICG needed to be informal, meaning they were an unpaid family member/friend who 
provides the majority of care to the PwPD21-23.  Participants were excluded if they 
received calories from enteral/parenteral nutrition, reported a HY stage 5, or scored ≤18 
on the T-MoCA. The sample size for this mixed-methods study included 10 dyads, with 
10 interviews total which has shown to be an appropriate number for data saturation in 
this population20, 28, 168-170 .  
This study was completed in 3 assessments, two-telephone calls and one home 
visit. The first assessment was a screening phone call with the primary author where the 
PwPD completed the T-MoCA and all participants reviewed inclusion criteria. The 
informed consent process was then conducted over the telephone. Assessment #2 was 
another telephone consisted of the DST and the first 24HR. All participants completing 
the 24HR recall were mailed a food amount booklet for estimating portion sizes. 
Assessment #3 was a home visit with the primary author, where the past medical history 
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(PMH), a second 24HR and a 21-question semi-structured interview were completed. 
Dyadic interviewing (inclusion of two people in one interview) was used during the 
second and third assessments, as this method has shown to provide insight to strengths 
and strategies for coping with sequelae171 
Qualitative Methods  
 Ten dyads were interviewed for this study (10 PwPD and their 10 caregivers). 
This sample size is consistent with past qualitative research to provide sufficient 
theoretical saturation (the point at which there is no significant new data) and yield 
sufficiently dense data with diverse experiences and perspectives20, 28, 168-170. Semi-
structured interview questions were created by the research team to explore Eating 
Environment, Dietary Intake, and Medication Management. The questions were piloted 
to 3 dyads prior to the start of this study in order to determine content validity and 
understandability of the survey. Based on these pilots, questions were formatted to be 
more directed to the PwPD, for example “How has your diet changed since you have 
been diagnosed with PD” these changes allowed more insight from the PwPD. Also, in 
order to identify where the knowledge gap is within the dyad, questions were formatted 
to be more open-ended, “Is there anything you would like to know about the foods you 
eat or your daily nutrition in general?” This question gave us great insight to the PLI the 
PwPD experienced as most addressed this concern during the interview. In the original 
interview, there was not a question about how long the PwPD have been on levodopa or 
how many times per day they take the medication, so this was added.  
 The interviews were conducted face-to-face at the participant’s home with the 
PwPD and their informal caregiver and primary author present. All interviews were 
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audio-recorded, transcribed verbatim and coded using thematic qualitative content 
analysis34.  The primary author and research assistant reviewed and coded the transcripts 
separately, then discussed their findings to identify the most common themes from each 
interview, and generated the final themes together. The two researchers then used nVivo 
11 QSR (International Pty Ltd, Victoria Australia) to code for final key themes as it is 
shown to be useful for enhancing the analytical capacity of qualitative data172. The final 
key themes for coding were: 1. Barriers to Dietary Intake, 2. Lack of Nutrition 
Knowledge for PD, 3. Reliance on ICG Buying and Preparing Foods, 4. Reduced 
Enjoyment of Foods and Meal Times, 5. Barriers to Medication Management, 6. 
Management of Symptoms, and 7. Access to Medication Information. Qualitative content 
was summarized and direct quotes were used to illustrate the perspectives of the 
participants. Participants with PD are identified in the text as “PD” followed by a number 
that was assigned sequentially as surveys were completed. The participants who were 
caregivers are identified in the text as “CG” followed by a number that was assigned 
sequentially as surveys were completed.  
Quantitative Methods 
 Nutritional risk status through use of the DST32 and nutritional intake through use 
of the Nutrition Data System for Research (NDSR). The DST is a 25-item questionnaire 
that identifies dietary patterns and nutritional risk. The sub components are: whole fruit 
and juice, vegetables, lean proteins, added fats, sugars and sweets, dairy and processed 
meats, and use of dietary supplements. A total score ranging from  0-105 was calculated 
and categorized with one of three different nutritional risk levels; (<60) at risk, (60-75) 
possible risk, and (>75) not at risk32. 
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 Two 24HR were collected using NDSR. Dietary intake data was gathered by the 
multiple-pass interview approach33, which included a respondent-driven 5-step process: 
1) Quick List to collect a list of foods and beverages consumed the previous day, 2) 
Forgotten Foods to probe for forgotten foods, 3) Time and Occasion to collect the time 
and eating occasion for each food, 4) Detail Cycle to collect a detailed description of each 
food including amount and additions, and review the 24HR day, 5) Final Probe to probe 
for anything else that has been consumed173.  
Additional Measures  
 Anthropometrics. Height was measured in cm by use of stadiometer (Detetco, 
Webb City Missouri), and weight will be measured in kg using a scale (Tanita BF-556, 
Arlington Heights, Illinois). Body mass index (BMI) was calculated by kg of body 
weight/height in meters2, and classified according to predetermined categories: 
underweight= <18.5kg/m2, normal weight= 18.5-24.9kg/m2, overweight= 25-29.9kg/m2 
and obese ≥30kg/m2 174.  
 Disease Staging. Self-reported HY scores were assessed as the disease stage from 
1, “unilateral disease”, 1.5 “unilateral plus axial involvement”, 2 “bilateral disease 
without impairment of balance”, 2.5 “mild bilateral disease with recovery on pull test”, 
or, 3 “mild to moderate bilateral disease, some postural instability, physically 
independent”31.   
 Past Medical History.  PwPD completed a medical history questionnaire to 
identify current and prior health-related conditions of PwPD. The topics addressed in this 
questionnaire included neurological, endocrine and cardiovascular health.  
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 Cognitive Functioning. The T-MoCA is a valid telephone test of cognition 
includes 8 subtests that consist of digit span, attention, calculation, repetition, verbal 
fluency, abstraction, recall and orientation175. Total possible score on this assessment is 
22. 
Statistical Analysis 
 Data from the questionnaires and home visits was analyzed using SPSS Version 
25 (IBM Corp, New York). Normality was assessed using skewness and kurtosis. 
Pearson’s correlations were used for the normally distributed data, and Spearman’s 
correlations were used for the data that was not normally distributed. Categorical 
variables are reported as numbers and percentages. Frequencies were used to determine 
which participants are at nutritional risk, possibly at risk and not at risk based on DST 
scores. Continuous variables are reported as mean ± standard deviation. The DST will be 
a continuous variable to identify the number and percent of participants found at nutrition 
risk, possible risk and not at nutrition risk. Data from the 24HR recalls is reported as 
mean macronutrient intake and g/kg protein consumed. Level of significance was set at a 
p-value of <0.05.  
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Appendix C: Consent forms for Research 
 
Knowledge, attitudes and behaviors for the dietary 
management of Parkinson’s disease Oral Consent Script for 
Research Consent for Caregiver 
 
“Before we begin, I want to review a few things with you.  
• Can you fluently speak English?  
• Are you 18 years or older?  
• Do you live at home?  
• Are you an unpaid caretaker of a person with Parkinson’s disease?  
• Do you have access to a telephone?  
• We will be completing a short questionnaire that will require you to recall 
words, identify letters and numbers, subtract, repeat phrases and make 
similarities (T-MoCA)”. 
 
BACKGROUND  
The purpose of this research study is to describe dietary knowledge, attitudes, and behaviors 
in regards to the protein-levodopa interaction as reported by people with Parkinson’s 
disease and their caregivers. Additionally, to better understand dietary quality and intake of 
people with Parkinson’s disease, nutrition risk status and dietary intake will be examined. 
This data will provide insight to healthcare professionals about what people with Parkinson’s 
disease and their caregivers understand and do about diet and levodopa management. 
 
You are being invited to take part in a research study. Before you decide to participate, it is 
important for you to understand why the research is being done and what it will involve. Ask 
us if there is anything that is not clear or if you would like more information. Take time to 
decide whether you want to volunteer to take part in this study. 
 
STUDY PROCEDURE  
This study will be completed at three Time Points that will all occur one month of each other. 
The first two Time Points will take place via telephone call, and the final will be a home visit. 
The total study time is expected to take three and one-half hours depending on how much you 
want to speak about each item on the questionnaires. The three time points are described 
below. Your participation in this interview is completely voluntary; you may choose not to 
participate. If there are any questions you do not wish to answer, just let me know and we can 
skip it. You can stop the interview at any time. Our conversation will be kept completely 
confidential and your responses will remain confidential. I am in a private office and will be 
using a speakerphone. No one else will be in the room with me. If you agree, our conversation 
will be tape-recorded in order to document your exact words. The tapes will be destroyed at 
the end of this project. The transcripts will be numbered and will not contain your name or 
any identifying information. 
 
Time Point #1 (~35 minutes) _  
• This will be completed on the phone.  
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• Review of inclusion and exclusion criteria. 
• Complete the informed consent process. 
 
Time Point #2 (~55 minutes)  
• This will be completed on the phone.  
• The inclusion of you and your caregiver in one interview (dyadic interviewing) will be 
used from this time point on, but, all dietary assessments (24- hour dietary recall and 
dietary screening tool) will be completed for people with Parkinson’s only as the 
scope of this study is the knowledge, attitudes and behaviors of people with 
Parkinson’s in regards to dietary recommendations, especially concerning protein 
due to the prominent food-drug interaction people with Parkinson’s may experience.  
• Complete the Dietary Screening Tool. The Dietary Screening Tool is a 25-item 
questionnaire that asks participants to report how frequently they consume various 
types of food and will detect dietary patterns. 
• Complete the first 24-hour. A 24-hour recall is a way to characterize nutritional intake 
and consists of 5- steps to collect all of the foods and beverages that you have 
consumed in the past 24 hours. The caretaker will be mailed a food amount booklet 
for estimating portion sizes after the first Time Point. 
 
Time Point #3 (~120 minutes)  
• This will be completed in-person – a study staff member will complete it as a home visit.  
• Complete the past medical history questionnaire. This questionnaire will 
identify current and prior health-related conditions. The topics addressed in this 
questionnaire will include neurological, endocrine and cardiovascular health. 
• Complete the second 24-hr dietary recall.  
• Complete the 21-question semi-structured interview. The study staff has designed 
this interview. You and your caretaker will be asked to answer questions about your 
eating environment, dietary intake, and medication management. 
 
RISKS  
The risks of this study are minimal. 
 
BENEFITS  
We cannot promise any direct benefit for taking part in this study. However, possible benefits 
include customized dietary recommendations for your caretaker based on their 24-hour 
recalls and the dietary screening tool answers. The recommendations will be generated by 
study staff and reviewed by the Principal Investigator and the doctoral nutrition student, who 
are registered dietitians, and sent to you approximately 1 month after Time Point #3. 
 
CONFIDENTIALITY  
We will keep all research records that identify you private to the extent allowed by law. 
You will be assigned a participant number that will be kept with your responses from 
the questionnaires, interview and dietary recalls. In publications, you will be identified 
as “participant #”. 
 
VOLUNTARY PARTICIPATION  
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Research studies include only people who choose to take part. You can tell us that you 
don’t want to be in this study. You can start the study and then choose to stop the study 
later. This will not affect your relationship with the investigator or any groups you may be 
involved in at the University of Rhode Island or related to Parkinson’s disease, and there 
will be no penalty of loss of benefits to which the participant is otherwise entitled. 
 
COSTS AND COMPENSATION TO PARTICIPANTS  
You will not receive any compensation for your time in this study. 
 
CONTACT INFORMATION  
If you have any additional questions about this study please feel free to contact the principal 
investigator, Dr. Ingrid Lofgren at 401-874-5706. You may also contact the Vice President for 
Research and Economic Development at 401-874-4576. 
 
CONSENT  
I will be turning on the tape recorded now. 
What questions do you have about the information that I have provided? 
Do you consent to participating in this research study? 
 
 
Knowledge, attitudes and behaviors for the dietary 
management of Parkinson’s disease Oral Consent Script for 
Research  
Consent for Person with Parkinson’s disease 
 
“Before we begin, I want to review a few things with you.  
• Do you fluently speak English?  
• Are you 18 years and older?  
• Do you have Parkinson’s disease with a Hoehn-Yahr staging of 1-4?  
• Do you live at home?  
• Are you currently taking 1 levodopa containing medication?  
• Do you have access to a telephone?  
• We will be completing a short questionnaire that will require you to recall 
words, identify letters and numbers, subtract, repeat phrases and make 
similarities (T-MoCA)”. 
 
BACKGROUND  
The purpose of this research study is to describe dietary knowledge, attitudes, and behaviors 
in regards to the protein-levodopa interaction as reported by people with Parkinson’s 
disease and their caregivers. Additionally, to better understand dietary quality and intake of 
people with Parkinson’s disease, nutrition risk status and dietary intake will be examined. 
This data will provide insight to healthcare professionals about what people with Parkinson’s 
disease and their caregivers understand and do about diet and levodopa management. 
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You are being invited to take part in a research study. Before you decide to participate, it is 
important for you to understand why the research is being done and what it will involve. Ask 
us if there is anything that is not clear or if you would like more information. Take time to 
decide whether you want to volunteer to take part in this study. 
 
STUDY PROCEDURE  
This study will be completed at three Time Points that will all occur one month of each other. 
The first two Time Points will take place via telephone call, and the final will be a home visit. 
The total study time is expected to take three and one-half hours, depending on how much 
you want to speak about each item on the questionnaires. The three time points are described 
below. Your participation in this interview is completely voluntary; you may choose not to 
participate. If there are any questions you do not wish to answer, just let me know and we can 
skip it. You can stop the interview at any time. Our conversation will be kept completely 
confidential and your responses will remain confidential. I am in a private office and will be 
using a speakerphone. No one else will be in the room with me. If you agree, our conversation 
will be tape-recorded in order to document your exact words. The tapes will be destroyed at 
the end of this project. The transcripts will be numbered and will not contain your name or 
any identifying information. 
 
Time Point #1 (~35 minutes) _  
• This will be completed on the phone. 
• Review of inclusion and exclusion criteria. This will include a short cognition test.  
• Complete the informed consent process. 
 
Time Point #2 (~55 minutes)  
• This will be completed on the phone.  
• Complete the Dietary Screening Tool. The Dietary Screening Tool is a 25-item 
questionnaire that asks participants to report how frequently they consume 
various types of food and will detect dietary patterns. 
• Complete the first 24-hour dietary recall. A 24-hour recall is a way to characterize 
nutritional intake and consists of 5- steps to collect all of the foods and beverages that 
you have consumed in the past 24 hours. You will be mailed a food amount booklet 
for estimating portion sizes after the first Time Point.  
• Your caregiver may participate with you at this time point but, all dietary 
assessments (24- hour dietary recall and dietary screening tool) will be based on your 
diet and typical food consumption as the scope of this study is the knowledge, 
attitudes and behaviors of people with Parkinson’s in regards to dietary 
recommendations, especially concerning protein due to the prominent food-drug 
interaction people with Parkinson’s may experience. 
 
Time Point #3 (~120 minutes)  
• This will be completed in-person – a study staff member will complete it as a home 
visit. This visit will include you and your caregiver.  
• Complete the past medical history questionnaire. This questionnaire will 
identify current and prior health-related conditions. The topics addressed in this 
questionnaire will include neurological, endocrine and cardiovascular health. 
• Complete the second 24-hr dietary recall.  
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• Complete the 21-question semi-structured interview. The study staff has designed 
this interview. You and your caregiver will be asked to answer questions about your 
eating environment, dietary intake, and medication management. 
 
RISKS  
The risks of this study are minimal. 
 
BENEFITS  
We cannot promise any direct benefit for taking part in this study. However, possible 
benefits include customized dietary recommendations based on their 24-hour recalls and 
the dietary screening tool. The recommendations will be generated by study staff and 
reviewed by the Principal Investigator and the doctoral nutrition student, who are 
registered dietitians, and sent to you approximately 1 month after Time Point #3. 
 
CONFIDENTIALITY  
We will keep all research records that identify you private to the extent allowed by law. 
You will be assigned a participant number that will be kept with your responses from 
the questionnaires, interview and dietary recalls. In publications, you will be identified 
as “participant #”. 
 
VOLUNTARY PARTICIPATION  
Research studies include only people who choose to take part. You can tell us that you 
don’t want to be in this study. You can start the study and then choose to stop the study 
later. This will not affect your relationship with the investigator or any groups you may be 
involved in at the University of Rhode Island or related to Parkinson’s disease, and there 
will be no penalty of loss of benefits to which the participant is otherwise entitled. 
 
COSTS AND COMPENSATION TO PARTICIPANTS  
You will not receive any compensation for your time in this study. 
 
CONTACT INFORMATION 
If you have any additional questions about this study please feel free to contact the principal 
investigator, Dr. Ingrid Lofgren at 401-874-5706. You may also contact the Vice President for 
Research and Economic Development at 401-874-4576. 
 
CONSENT  
I will be turning on the tape recorded now. 
What questions do you have about the information that I have provided? 
Do you consent to participating in this research study? 
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Appendix D: Assessment Materials 
 
 
 
 
 
Participants will complete two 24-hour recalls (24HR).  The first 24HR will be done over the 
phone (assessment #2) b and the second 24HR will be done in-person during a home visit 
(assessment #3).  A 24HR is when a person is asked to list and describe all the foods they 
ate the previous day.  Since people consume different foods and beverages, different 
questions are asked during each 24HR.  Participants will be encouraged to have labels of 
foods they eat available during the assessments so exact information can be entered.  This 
project will be utilizing the Nutrition Data System for Research from the University of 
Minnesota to collect the dietary data.  Information on the program is attached. 
 
For the most part, all participants will be asked the following questions.  Many of these 
questions will be asked multiple times. 
• At what time did you get up yesterday? 
• What was the first thing you had to eat or drink after getting up yesterday? 
• What else did you have to eat with that (insert food or beverage)? 
• What was added to that beverage? 
• What else did you have at that meal? 
• Was the (insert food or beverage) eaten plain or did you put something on it? 
• What did you eat after that meal? 
• What did you have for snacks yesterday? 
• What was the brand of (insert food or beverage)? 
• How many cans/bottles or juice/soda/water did you have at that time? 
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• What was the last thing you ate and drank yesterday? 
• What did you snack on after you last meal? 
• Did you get up during the night and eat anything? 
• About what size was the (insert food or beverage)? 
• Was the (insert food or beverage) an original product or was it modified in anyway?  
For example, was it low sodium, low fat, cholesterol free, etc.? 
• When was the first time you took your levodopa or levodopa containing medication?  
• When was the next time you took your levodopa or levodopa containing medication? 
Did you have anything to eat at this time?   
Depending on dietary intake, these additional questions may be asked.  Many of these 
questions could be asked multiple times. 
• Did you add any cream, milk, milk substitute to the coffee or tea? 
• Did you add any sugar or sugar substitute to the coffee or tea? 
• How much of the (insert food or beverage) did you eat? 
• Were you able to finish all of that (insert food or beverage)?  
• Was this (insert food) prepared with fat? If so, what type of fat? 
• When preparing (insert food) was salt added?  
• Was there frosting on the (insert food)? 
• If so, about how much frosting? 
• What was the flavor/color of the frosting? 
• Did you add any condiments to (insert food)? 
• If so, what condiments and how much of each? 
• Was there ice in the (insert beverage)? 
• Was the cake a single, double, or triple layer cake? 
• Were there any seeds on the bagel? 
 
 
Dietary Screening Tool 
 
 
DIRECTIONS: Please check one response to each question that best describes 
how you eat.  
 
 
How often do you usually eat fruit as a snack? 
____ Never  
____ Less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you usually eat whole grain breads? 
____  Never or less than once a week 
____  1 or 2 times a week 
____  3 or more times a week 
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How often do you usually eat whole grain cereals? 
____  Never or less than once a week 
____  1 or 2 times a week 
____  3 or more times a week 
 
How often do you usually eat candy or chocolate? 
____  Never  
____ Less than once a week 
____  1 or 2 times a week 
____  3 or more times a week 
 
How often do you eat crackers, pretzels, chips, or popcorn? 
____  Never  
____  Less than once a week 
____  1 or 2 times a week 
____  3 or more times a week 
 
How often do you eat cakes or pies? 
____  Never  
____  Less than once a week 
____  1 or 2 times a week 
____  3 or more times a week 
 
How often do you eat cookies? 
____  Never  
____  Less than once a week 
____  1 or 2 times a week 
____  3 or more times a week 
 
How often do you eat ice cream? 
____  Never  
____  Less than once a week 
____  1 or 2 times a week 
____  3 or more times a week 
 
How often do you eat cold cuts, hot dogs, lunchmeats or deli 
meats? 
____ Never  or less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you eat bacon or sausage? 
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____ Never  or less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you eat carrots, sweet potatoes, broccoli, or 
spinach? 
____ Never  
____ Less than once a week 
____ 1 or 2 times a week 
____ 3 or more times a week 
 
How often do you eat fruit (not including juice)? Please include 
fresh, canned or frozen fruit. 
____ Never or Less than once a week 
____ 1 or 2 times a week 
____ 3 to 5 times a week 
____ Every day or almost every day  
 
How often do you eat hot or cold breakfast cereal? 
____  Never  
____  Less than once a week 
____  1 or 2 times a week 
____ 3 to 5 times a week 
____  Every day or almost every day  
 
 
How often do you drink some kind of juice at breakfast? 
____ Never or Less than once a week 
____ 1 or 2 times a week 
____ 3 to 5 times a week 
____ Every day or almost every day  
 
How often do you eat chicken or turkey? 
____ Never or less than once a week 
____ 1 or 2 times a week 
____ More than 3 times a week 
 
How often do you drink a glass of milk? 
____ Never or Less than once a week 
____ 1 or 2 times a week 
____ 3 to 5 times a week 
____ Every day or almost every day  
____ More than once every day 
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Do you usually add butter or margarine to foods like bread, 
rolls, or biscuits? 
____ Yes   
____ No 
 
Do you usually add fat (butter, margarine or oil) to potatoes and 
other vegetables? 
____ Yes   
____ No 
 
Do you use gravy (when available) at meals? 
____ Yes   
____ No 
 
Do you usually add sugar or honey to sweeten your coffee or 
tea? 
____ Yes   
____ No 
  
Do you usually drink wine, beer or other alcoholic beverages? 
____ Yes   
____ No 
 
How often do you eat fish or seafood that IS NOT fried? 
____ Never  
____ Less than once a week 
____ Once a week 
____ More than once a week  
 
How many servings of milk, cheese, or yogurt do you usually 
have each DAY? 
____ None  
____ One  
____ Two or more  
 
How many different vegetable servings do you usually have at 
your main meal of the day?  
____ None  
____ One  
____ Two  
____ Three or more 
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Which of the following best describes your nutritional 
supplement use. 
____  I don’t use supplements  
____  I use supplements other than vitamins and mineral 
____  I use a multivitamin/mineral preparation (e.g. Centrum) 
 
 
 
INTERVIEW 
Knowledge, attitudes and behaviors for the dietary management of 
Parkinson’s disease 
Ingrid Lofgren, PhD, Principal Investigator 
Leslie Mahler, PhD, CCC-SLP, co-Investigator 
Version 1: 7-3-13 
 
Participant Name:_________________________   Initials: ___  ___  ___  ID#:  
______________  
 
Name of Interviewer:_____________________________                    
Date:_________________  
Emergency contact name and address & phone:     
                  
 _______________________________________ 
                  
 _______________________________________ 
               
DIRECTIONS:   Read the following questions out loud to each prospective volunteer 
and record the answers. Any answers that require clarification should be written in the 
space below the question or on the back of the sheet.  Indicate whether any follow-up is 
necessary or if any referrals are appropriate. 
 
What is your neurological diagnosis? __________________________ 
When were you diagnosed? _________________________________ 
What were your symptoms at that 
time?____________________________________________ 
________________________________________________________________________
____ 
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What are your symptoms now? 
___________________________________________________ 
________________________________________________________________________
_____ 
What is your communication 
like?_________________________________________________ 
________________________________________________________________________
_____ 
What is your diet like? 
___________________________________________________________ 
What is your physical activity like? 
_________________________________________________ 
Does your speech sound clear to other people? 
_________________________________________ 
 If not, how does it sound? 
___________________________________________________ 
Can you think of the words that you want to say? 
______________________________________ 
If you do have trouble, how often does it happen? 
__________________________________ 
Are you experiencing any symptoms of a swallowing disorder? 
_____________________________ 
If yes, what is the problem with your swallowing? 
__________________________________ 
________________________________________________________________________
_____ 
What would you say is your most significant problem with speech or swallowing today? 
________________________________________________________________________
______ 
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Did you experience any changes in your speech or swallowing before your diagnosis? 
________ 
________________________________________________________________________
_____ 
Does medication affect your speech or voice or swallowing? _________ If yes, in what 
way? 
________________________________________________________________________ 
Speech 
How many hours of speaking do you do in a day? 
____________________________________ 
What is a typical day of communicating like for you? 
__________________________________ 
________________________________________________________________________
_____ 
Do you pronounce your words clearly? 
____________________________________________ 
Do people ask you to repeat yourself? 
______________________________________________ 
Do people have a hard time understanding you? 
______________________________________ 
What do you do when you want to be as easy to understand as possible? 
__________________ 
________________________________________________________________________
_____ 
What percent of your speech do you think is understandable? 
____________________________ 
Has your neurological diagnosis caused you to talk less? 
________________________________ 
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If so, how much less? _____________ Why? 
____________________________________ 
________________________________________________________________________
_____ 
 
Swallowing 
Do you have any difficulty with swallowing? ___________________________________ 
Do you cough during mealtimes? _____________________ 
If yes, do you cough more with water or solid food? 
_________________________________   
Do you have difficulty making the food go down (need to swallow twice)? 
____________ 
Does it take you longer to finish a meal than before your neurological diagnosis? 
________________ 
Have you experienced any unintentional recent weight loss? _____________ 
Have you ever been diagnosed with pneumonia? ____________ If yes, when? 
_____________ 
Have you changed your diet since your neurological diagnosis? ___________________ 
If yes, what did you modify? ___________________________________ 
 
Musculoskeletal system: 
Has your doctor ever told you that you have:  (circle all that apply) 
• Osteoarthritis or degenerative arthritis                                                                
• Rheumatoid arthritis                                                                                            
• Osteoporosis                         
• Ankylosing Spondylitis                                                                                       
• Unknown or other type of arthritis                                                                      
• Any other disease of joint or muscle: 
• Comments:           
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Cardiovascular system: 
• Has any family member had a heart attack prior to the age of 55?          
o If so, how are they related to you?                     
• Have you ever had frequent cramping in your legs while resting?                      
o If yes, is it a current problem?        _____________________________                                     
• Have you ever had pain or cramping in your legs while walking?                         
o If yes, is it a current problem?     ________________________________                                      
  
•  If yes, is this pain relieved by rest or by discontinuing walking? 
• Have you ever been told that you have high blood pressure 
o If yes, what was the date of onset? ____________________ 
o Were you given any medications?       ______________                                                      
• Did a doctor ever tell you that you had a heart problem?                                      
o If yes: What was the date of onset? _______________________ 
• What did the doctor call it? _________________________________ 
o Were you given any medications?   ____________________________  
•   Do you have any history of high cholesterol in your blood as evidenced by  a 
previous blood lipid tests?
 ________________________________________________________ 
Comments:   ______________________     
Endocrine system: 
Have you ever had any of the following: Thyroid problems, adrenal problems, 
diabetes mellitus? 
• ________________________________________________________________ 
  
• If yes to diabetes, which type? Type 1 or Type 2     
  Date of onset- _________________________ 
            Are/were you on any medication, or is it diet controlled? 
_________________________ 
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Neurological system: 
• Do you have any significant problems with your memory? (circle all that apply) 
o When answering the telephone, do you recall what you were doing 
before it rang?           
o Can you give the directions to your house/apartment?  
o Can you keep appointments without a reminder? 
o Can you remember what clothes you wore yesterday?                     
• Any problems with vision other than corrective lens changes?                     
o If yes, which of the following conditions- Blindness, temporary loss    
of vision, double vision, glaucoma, cataract, macular degeneration or 
others. 
____________________________________________________________
__  
Do you have and of the following?: (circle all that apply) 
• Vertigo (a feeling of spinning, or unsteadiness)                
• Seizure or convulsions?    
• Migraine or severe headaches?                         
• Paralysis of arm or leg?                                     
• A head injury with loss of consciousness?     
• Pain, numbness or tingling in your limbs?             
• Pain in your lower back?  
• Do you have pain in any part of body including headaches while exercising? 
                               
• Have you been told that you have a peripheral neuropathy?                   
• Tremors?                                    
• Problems with walking? If yes, 
o Do you fall frequently?                       
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o Is your walking problem related to pain, weakness or loss of balance?   
                        
• Have you ever had an operation on skull or brain?          
       
• Have you ever had meningitis or Brain fever?          
       
Comments:          
Previous Treatment 
Have you had previous speech or swallow treatment, occupational therapy or physical 
therapy? __________________________________________ 
If yes, please describe (when, what) 
_______________________________________________ 
________________________________________________________________________
____ 
Was it beneficial? 
_____________________________________________________________ 
If yes, what changes did you notice? 
______________________________________________ 
________________________________________________________________________
____ 
Employment 
Are you employed? 
___________________________________________________________ 
Type of employment 
__________________________________________________________ 
How much speaking do you do at your job? 
___________________________________________ 
________________________________________________________________________
____ 
  
 
97 
Other 
Have you noticed any difficulty with your memory? _____________________________ 
Have you experienced any changes in your mood? 
_______________________________ 
Is it difficult for you to pay attention long enough to finish a task? 
___________________ 
Do you have any difficulty reading? ____________________________________ 
Do you have any difficulty writing? ___________________________________ 
Do you have any other health problems or conditions that would affect communication, 
nutrition or physical activity?   
________________________________________________________________________
_____ 
________________________________________________________________________
_____ 
Semi-Structured Interview Questions 
Eating Environment:  
1. Describe the most challenging aspects of preparing and eating meals since the 
diagnosis of Parkinson’s disease. 
2. Who is responsible for buying and preparing food in your home? 
Dietary Intake: 
1. How has your diet changed since being diagnosed with Parkinson’s disease?  
Prompt: Are there any foods that you have stopped or increased eating due to 
your diagnosis?  
2. How would you describe your current diet? Prompt: Are you following any 
special diet?  
3. Who have you spoken with about your diet and what have they told you?  
Prompt: What instructions have you been given and by whom? 
4. Is there anything that you would like to know about the foods that you eat or 
your daily nutrition in general? Probe: What questions or concerns about your 
daily eating or about the foods you eat in general?  
5. What is your understanding of a Protein Redistribution diet or a Low Protein 
diet?  Prompt: The Protein Redistribution diet limits protein during the day and 
includes more protein at dinner; the Low Protein diet limits protein during the 
day and at dinner. 
6. What challenges would you anticipate if you were following a Protein 
Redistribution or Low Protein diet?  
7. What difficulties do you have chewing or swallowing your food or beverages? 
Prompt: What fluids to you have difficulty consuming? How often do you 
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cough during meals? How much more time does it take you to eat than before 
the diagnosis?  
8. Do you modify the textures or consistencies of your foods and beverages? 
Prompt: Do you consume ground meat instead of whole pieces? Do you soften 
or pureed your vegetables? Do you use products like “Simply Thick” to thicken 
the fluids you consume?  
Medication Management: 
1. Describe your greatest challenges to taking your levodopa medication as 
prescribed by your doctor?  
2. How do you cope or overcome the challenges to taking you levodopa 
medication as prescribed by your doctor? 
3. What is your daily levodopa schedule?  
4. What information have your doctor and pharmacist provided about the timing 
of your medications? 
5. How do you time your food and medication intakes? 
6. How do you obtain information about your levodopa medication? 
7. How well does levodopa manage your daily symptoms? Prompt: Do you ever 
feel shaky, unsteady or sluggish after consuming your medication?  
8. What do you know about food-drug interactions between levodopa and protein?  
9. What information would you like to know about your medication management?  
Probe: How interested are you in learning more? 
10. Do you rely on your caregiver to receive your levodopa medication? 
Final Questions 
1. Is this anything else about maintaining a healthy diet that works with your 
Parkinson medications that you want to share? 
2. Is there anything else you would like to share regarding your journey with 
Parkinson’s that you would like to share?  
 
